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Abstract 
 
Emerging evidence suggests that pulmonary iron accumulation is implicated in a spectrum of 
chronic and acute lung diseases, such as cystic fibrosis and pulmonary alveolar proteinosis. In 
patients with chronic obstructive pulmonary disease, iron deposits in alveolar macrophages and 
the percentage of iron loaded macrophages is associated with increased disease severity. On 
the other hand thalassemia major, a disease characterized by transfusional iron overload, has 
been associated with impaired lung function. However, the mechanism(s) involved in pulmonary 
iron deposition and its role in the in vivo pathogenesis of lung diseases remained unknown.  
The supply of iron to the lung depends on its systemic plasma availability, which is controlled by 
the hepcidin/ferroportin regulatory axis. The work presented here aims to understand whether a 
disruption in the hepcidin/ferroportin regulatory system and the subsequent increase in systemic 
iron levels affect lung iron homeostasis and function. To achieve this goal, we took advantage of 
a murine disease model of hereditary hemochromatosis type 4 (Slc40a1C326S), hallmarked by a 
C326S amino acid substitution in ferroportin that impairs hepcidin binding. 
We show that resistance of ferroportin to hepcidin binding causes pulmonary iron accumulation 
in defined lung cell types. The increase in pulmonary iron levels correlates with an increase in 
lipid peroxidation, suggesting that iron-mediated oxidative stress could contribute to the 
pathogenesis of lung diseases. Measurements of lung function in aged Slc40a1C326S/C326S mice 
revealed classical signs of restrictive lung disease, such as a decrease in total lung capacity and 
lung compliance. Furthermore, Slc40a1C326S/C326S mice show a severe decrease in blood oxygen 
saturation when compared to wild-type animals. Taken together, these findings implicate iron 
overload in lung pathology, which is so far not considered a classical iron-related disorder. 
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Resumo 
 
A acumulação de ferro nos pulmões está associada a um largo espectro de doenças 
respiratórias, tais como a fibrose quística e a proteinose alveolar pulmonar. Em pacientes com 
doença pulmonar crónica obstrutiva, a deposição de ferro foi detectada em macrófagos 
alveolares e a percentagem de macrófagos com acumulação de ferro foi associada ao grau de 
severidade da doença. Por outro lado, pacientes com formas severas de talassemia (uma 
doença caracterizada por elevados níveis sistémicos de ferro) apresentam frequentemente 
alterações da função pulmonar. No entanto, o(s) mecanismo(s) envolvido(s) na acumulação de 
ferro nos pulmões e o papel do ferro na patologia de doenças respiratórias ainda não é 
conhecido. 
O fornecimento de ferro às células do pulmão depende da sua disponibilidade sistémica na 
corrente sanguínea, a qual é controlada pela sistema regulatório hepcidina/ferroportina. O 
trabalho apresentado nesta tese teve como objectivo perceber como é que uma disrupção no 
sistema hepcidina/ferroportina e o consequente aumento nos níveis sistémicos de ferro afectam 
a homeostase de ferro no pulmão e a função pulmonar. Para atingir este objectivo, analisámos 
um ratinho modelo da doença hemocromatose hereditária tipo 4 (Slc40a1C326S), que é 
caracterizado pela substituição de uma cisteína por uma serina na posição 326 da ferroportina. 
Esta mutação na ferroportina impede a ligação da hepcidina. 
Nesta tese mostramos que uma disrupção no sistema regulatório hepcidina/ferroportina causa 
acumulação de ferro no pulmão, a qual é restricta a tipos celulares específicos. O aumento dos 
níveis de ferro neste orgão está associado a um aumento na peroxidação de lípidos, o que 
sugere que o stress oxidativo mediado por ferro pode contribuir para a patogénese de doenças 
pulmonares. Testes de função pulmonar em ratinhos Slc40a1C326S/C326S com 9 meses revelaram 
sinais característicos de doença pulmonar restritiva, tal como uma diminuição da capacidade 
pulmonar total e da compliance pulmonar. Além disso, ratinhos Slc40a1C326S/C326S apresentam 
uma redução severa na saturação de oxigénio no sangue. Em conclusão, estes resultados 
revelam uma contribuição do aumento dos níveis de ferro na etiopatogenia de doenças 
pulmonares, as quais até agora não têm sido consideradas doenças tipicamente associadas a 
alterações na homeostase do ferro. 
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1. Mammalian Iron Homeostasis 
  
1.1 Biological role of iron 
Iron is one of the most abundant elements in the crust of the Earth and it plays a key role in the 
biology of almost all living organisms. It has the remarkable ability to exist in multiple oxidation 
states, ranging from -2 to +6; the divalent ferrous (Fe2+) and the trivalent ferric (Fe3+) being the 
most common species [1]. By readily accepting and donating electrons, iron acts as an important 
co-factor for enzymes and proteins involved in fundamental metabolic processes, such as DNA 
synthesis (e.g. ribonucleotide reductase), oxygen transport (e.g. hemoglobin), and mitochondrial 
respiration (e.g. cytochromes) [1]. However, this ability to fluctuate between different oxidation 
states also explains why free iron is very reactive and potentially toxic. Iron catalyzes the 
formation of reactive oxygen species (ROS) through “Fenton-type” reactions [2]. These highly 
reactive radicals can damage lipids, proteins, and nucleic acids, leading to cellular damage and 
tissue injury [3]. 
The binding of iron to proteins and prostethic groups counteracts its chemical reactivity and 
potentially deleterious effects. Nevertheless, iron levels must be strictly controlled in order to 
meet the cellular and systemic metabolic needs while preventing detrimental iron overload. 
  
1.2 Iron distribution 
The average adult human body contains 3-4 grams (g) of iron. Even though all cells contain 
small amounts of iron in iron-containing proteins, most of the body’s iron is present in the 
hemoglobin of erythrocytes (2-3 g). Iron is delivered to tissues and cells through the 
bloodstream, which contains 2-4 mg of iron bound to the iron-transport protein transferrin 
(reviewed in [4]). 
1.3 Iron absorption, utilization, storage, and recycling 
Iron absorption 
Dietary iron is mainly found in the form of ferric iron (Fe3+) or associated with heme groups and 
is absorbed by duodenal enterocytes. Since there is no regulated pathway to excrete iron from 
the organism, the control of intestinal iron absorption is crucial to maintain adequate body iron 
levels (reviewed in [5]). Inorganic Fe3+ needs to be reduced to Fe2+ by the membrane-associated 
ferrireductase duodenal cytochrome B (DcytB) before being transported to the cytosol via the 
divalent metal transporter 1 (DMT1) expressed in the brush-border membrane of enterocytes 
General Introduction 
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(Figure 1.1) [6, 7]. Heme iron is absorbed by an independent mechanism that is not clearly 
known yet. Subsequently, iron is released intracellularly from heme by heme oxygenase (HO) 1 
[8]. Cytosolic iron can be used for metabolic processes or exported into the bloodstream via the 
only known cellular iron exporter ferroportin expressed in the basolateral membrane of 
enterocytes (Figure 1.1) [9, 10]. The export of iron via ferroportin is coupled with the reoxidation 
of Fe2+ to Fe3+, a process that is catalyzed by hephaestin, a trans-membrane ferroxidase [11]. 
Ferric iron is then loaded onto the glycoprotein transferrin, which has two high-affinity sites for 
Fe3+ [12]. By maintaining iron in a chemically inert form, iron binding to transferrin prevents the 
generation of reactive radicals and allows its delivery to every cell of the organism. 
 
Cellular iron uptake, utilization, and storage 
Cells take up transferrin bound iron via transferrin receptor 1 (TfR1). The binding of diferic 
transferrin (Tf-Fe
2
) to TfR1 triggers the endocytosis of the Tf-Fe
2
/TfR1 complex via clathrin-
coated vesicles [13]. The acidification of endosomes leads to conformational changes in TfR1 
and transferrin and the subsequent release of iron [14]. Upon reduction of ferric iron to ferrous 
iron by metalloreductase Six Transmembrane Epithelial Antigen of the Prostate 3 (STEAP3), 
iron is transported to the cytosol via DMT1 [15, 16]. Transferrin and TfR1 are recycled to the cell 
surface and can be reutilized [13]. 
Iron trafficking within the cells is still poorly understood but it is known that most of the 
intracellular iron is directed towards the mitochondria where it is used for Fe-S cluster biogenesis 
and heme synthesis [17-19] (reviewed in [20]). A small fraction of the total cellular iron (<5%) is 
maintained in a pool of redox-active iron complexes, the Labile Iron Pool (LIP), for immediate 
metabolic needs [21]. Excess iron that is not used for metabolic processes is stored in ferritin, an 
ubiquitous multimeric protein composed by 24 subunits of heavy and light chains that can 
accommodate up to 4500 iron atoms [22]. Ferritin allows cells to store iron in a redox inactive 
form, preventing iron-mediated oxidative stress. Even though most cell types can store small 
amounts of iron intracellularly in ferritin, hepatocytes in the liver and splenic macrophages are 
the major reservoirs for iron in the organism (reviewed in [4]). When needed, these cells can 
rapidly export iron to the bloodstream via the iron exporter ferroportin (a process coupled with 
the reoxidation of Fe2+ to Fe3+ by the multicopper oxidase ceruloplasmin) (Figure 1.1) [23]. 
Since TfR1 is ubiquitously expressed, it is believed that transferrin mediated iron uptake occurs 
in most cell types. Nevertheless, this cycle is particularly important to deliver a very large amount 
of iron to erythroid progenitors in the bone marrow for hemoglobin synthesis. 
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Iron recycling 
The daily demand of iron for hemoglobin synthesis is 20-25 mg. However, under normal 
circumstances only 1-2 mg of iron per day is absorbed by enterocytes from dietary sources, 
which compensates for small iron losses mainly due to desquamation of epithelial surfaces or 
minor bleeding (reviewed in [4]). Most of the iron needed for erythropoiesis is provided by a very 
efficient recycling system (reviewed in [24]) (Figure 1.1). Aged or damaged erythrocytes are 
phagocytosed by reticuloendothelial macrophages, degraded within the phagolysosome and 
hemoglobin-derived heme is exported across the phagolysosomal membrane to the cytosol by 
the transmembrane heme permease HRG-1 (mammalian homologue heme responsive gene 1) 
[25]. In the cytosol, heme is catabolized by HO1 and iron is released [26, 27]. The export of 
cytosolic iron from macrophages back to the bloodstream occurs via ferroportin and is coupled 
to the activity of the multicopper oxidase ceruloplasmin, a homologue of hephaestin (Figure 1.1) 
[23]. Ferric iron binds to transferrin and can be reutilized for a new cycle of erythropoiesis. 
It is worth to mention that the contributions of dietary iron absorption and recycling to the daily 
turnover differ between different species, depending on the daily iron losses and the lifetime of 
erythrocytes (reviewed in [28]). 
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Figure 1.1 – Systemic iron homeostasis. Left panel: Dietary iron absorption occurs at the brush-border membrane 
of duodenal enterocytes. Ferric iron is reduced to ferrous iron by Duodenal cytochrome B (DcytB) and is transported 
across the membrane via Divalent metal transporter 1 (DMT1). Heme iron is taken up by an unknown mechanism and 
iron is released from heme intracellularly by heme oxygenase 1 (HO1). The export of iron across the basolateral 
membrane of enterocytes occurs via ferroportin (FPN) and is coupled with the reoxidation of ferrous to ferric iron – a 
process that is catalyzed by hephaestin. In the blood, ferric iron circulates bound to transferrin (Tf-Fe2). Center lower 
panel: Transferrin-bound iron can be taken up via Transferrin receptor 1 (TfR1) by every cell type in the organism, 
including hepatocytes which store high amounts of iron in ferritin. Hepatocytes can also take up high amounts of non-
transferrin-bound iron (NTBI) via ZIP14. When required, iron can be exported from hepatocytes via FPN back to 
circulation (a process coupled with the reoxidation of Fe
2+
 to Fe
3+
 by ceruloplasmin). Right panel: Senescent 
erythrocytes are engulfed by reticuloendothelial macrophages. Iron is released from heme by HO1 and it can be either 
stored in ferritin or released to circulation, depending on the body iron needs. Iron export from macrophages via FPN 
is also coupled with the activity of ceruloplasmin. Center upper panel: Hepcidin produced by hepatocytes has the 
ability to decrease cellular iron export by binding to FPN and promoting its internalization and degradation. Hepcidin 
expression is controlled by several factors: body iron stores, inflammation, erythropoietic signals and hypoxia. Image 
created based on image from Darshan et al., 2010 [29]. 
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1.4 Cellular Iron Homeostasis 
The coordination between cellular iron uptake, utilization, storage, and export is crucial to 
maintain cellular iron homeostasis: cells must have sufficient iron to meet their metabolic needs 
while avoiding toxic iron overload. The post-transcriptional regulatory system IRE/IRP plays a 
critical role in this process by controlling the expression of iron-related proteins according to 
intracellular levels of iron (Figure 1.2) (reviewed in [30] and [31]). It relies on the cytosolic iron 
regulatory protein 1 and 2 (IRP1 and IRP2) and their interaction with conserved hairpin 
structures known as iron-responsive elements (IREs) present in the 5’ or 3’ untranslated regions 
(UTRs) of mRNAs of several iron-regulated genes. Transcripts containing IREs in the 3’ UTR are 
stabilized after the binding of IRPs whereas the translation of transcripts containing an IRE in the 
5’ UTR is blocked upon IRP binding. 
In iron-depleted cells, IRPs bind to the IRE in the 5’ UTR of ferritin light chain (FtL), ferritin heavy 
chain (FtH), and Fpn mRNA, inhibiting their translation [9, 10, 32, 33]. IRPs bind also to IREs in 
the 3’ UTR of TfR1 mRNA and to a single IRE in the 3’ UTR of Dmt1 mRNA, blocking their 
degradation [34-36]. This leads to increased iron uptake and decreased iron storage and export, 
resulting in higher intracellular iron availability. In iron-replete cells, IRP1 is converted from its 
RNA-binding form to the cytoplasmatic aconitase form containing a [4Fe–4S] cluster and IRP2 is 
targeted to proteasomal degradation [37-39]. Consequently, IRPs cannot bind to IREs. This 
leads to increased iron storage and export by increasing ferritin and Fpn mRNA translation and 
decreased iron uptake due to increased degradation of TfR1 and Dmt1 mRNAs. 
The vital role of the IRE/IRP regulatory system is highlighted by the observation that genetic 
ablation of IRP1 and IRP2 in the mouse results in early embryonic lethality [40]. Interestingly, 
animals lacking only one of the IRPs are viable but present different phenotypes [41, 42], 
indicating that the two IRPs have only partially redundant functions (reviewed in [43]). 
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Figure 1.2 – Cellular iron homeostasis: IRE/IRP system. IRPs bind to IREs located in either the 5’ 
UTR or 3’ UTR of mRNAs and regulate their translation and stability, respectively. In iron-depleted 
cells, IRPs bind to an IRE localized in the 5’ UTR of mRNAs and repress their translation whereas the 
binding to IREs in the 3’ UTR stabilizes the mRNAs. In high iron conditions, IRPs do not bind to IREs 
leading to the translation of mRNAs containing an IRE in the 5’ UTR and to the degradation of 
mRNAs containing IREs in the 3’UTR. This mechanism counterbalances both cellular iron deficiency 
and iron overload. Adapted from Anderson et al., 2012 [30]. 
 
1.5 Systemic Iron Homeostasis 
Adequate plasma iron levels are crucial for the correct iron supply and homeostasis of different 
tissues and cells. In humans, approximately 30% of plasma transferrin is saturated with iron. A 
transferrin saturation below 16% reflects an iron deficient condition whereas a saturation above 
45% indicates iron overload. If the transferrin saturation exceeds 60%, non-transferrin-bound 
iron (NTBI) accumulates in circulation and can easily lead to cell and tissue damage [44]. NTBI 
can be rapidly taken up by the liver (and to a lesser extent by other organs, as the heart), 
probably via Zrt/IRT-like protein (ZIP) 14 (Figure 1.1) [45]. Another member of the ZIP proteins, 
ZIP8, has also been reported to transport NTBI and is mainly expressed in the lung and placenta 
[46]. 
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The coordination of iron fluxes from tissues to circulation is essential to maintain transferrin 
saturation at physiological levels and is mainly controlled by the hepcidin/ferroportin regulatory 
system (Figure 1.1) (reviewed in [5]). 
 
1.5.1 Hepcidin/Ferroportin Axis 
Hepcidin is a 25 amino acid peptide hormone synthesized and secreted to the plasma by 
hepatocytes [47]. It emerged as a key molecule in systemic iron homeostasis due to its ability to 
regulate cellular iron efflux: hepcidin acts by post-translationally controlling the plasma 
membrane concentration of ferroportin (reviewed in [5] and [28]). Ferroportin (FPN), a protein 
containing 12-transmembrane domains, is the only known cellular iron exporter [9, 10, 48]. It is 
highly conserved and has been identified in several vertebrates as well as in species as distant 
as Caenorhabditis elegans (reviewed in [28]). Ferroportin expression is abundant in cells that 
handle major iron fluxes such as duodenal enterocytes, kupffer cells and splenic macrophages, 
and to a lesser extent in hepatocytes. 
Hepcidin binding to ferroportin induces its ubiquitination, internalization, and subsequent 
lysosomal degradation [49, 50]. This leads to a decrease in iron export from ferroportin-
expressing cells and therefore lowers systemic iron levels. 
1.5.2  Regulation of hepcidin expression  
The expression of hepcidin in hepatocytes rapidly responds to different stimuli, such as systemic 
iron levels, inflammation, erythropoietic activity, and hypoxia (Figure 1.1). A dysregulation of 
hepcidin production leads to iron-related disorders. 
The production of hepcidin by other cell types has been described in the literature but at a much 
lower level [51-54] and its role in systemic iron homeostasis is not clear yet. 
 
Hepcidin regulation by systemic iron availability 
Hepcidin plays a central role in the regulation of systemic iron levels. Conversely, its expression 
is regulated by plasma iron levels and iron stores. Mice maintained on a high iron diet increase 
hepatic hepcidin expression in order to decrease the levels of circulating iron whereas a low iron 
diet induces the opposite response [55]. 
The bone morphogenic protein (BMP)/mothers against decapentaplegic homologue (SMAD) 
pathway has been described as the key signaling system for the regulation of hepcidin. Through 
a yet to be identified mechanism, BMP6 levels are increased in conditions of iron overload [56]. 
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BMP6 binds and activates the BMP serine/threonine kinase receptors expressed at the cell 
membrane of hepatocytes, which leads to the phosphorylation of the SMAD1/5/8 complex [56-
58]. This complex recruits SMAD4 and translocates to the nucleus, inducing hepcidin 
transcription (reviewed in [59]). Consistently, BMP6 knock out mice show hepcidin deficiency 
and iron overload [60, 61]. A recent study showed that BMP6 is mainly produced by liver 
endothelial cells and that loss of BMP6 specifically in these cells recapitulates the 
hemochromatosis phenotype observed in the global BMP6 knock out mice [62]. BMP2 and 
BMP4 were shown to also up-regulate hepcidin expression in vitro [63]. The in vivo role of BMP2 
in controlling hepcidin expression has recently been confirmed by Koch and colleagues [64]. 
The activation of the BMP signaling is enhanced by the BMP co-receptor hemojuvelin (HJV) 
[65]. Under iron deficient conditions, the transmembrane protease serine 6 (TMPRSS6, also 
known as matriptase 2) and the protease furin cleave HJV, abrogating its function as a BMP co-
receptor and negatively regulating hepcidin expression [66, 67]. Attenuation of hepcidin 
activation can also be achieved through a negative feedback regulatory system mediate by 
SMAD proteins, such as SMAD7 [68]. 
The sensing of extracellular iron occurs by the interaction of transferrin-bound iron 
(holotransferrin) with a complex composed of TfR1, TfR2 (homologous to TfR1 but with lower 
affinity to holotransferrin), and human hemochromatosis protein (HFE), which is also expressed 
at the cell surface of hepatocytes and interacts with both TfR1 and TfR2 (reviewed in [5]). The 
interaction of HFE with TfR1 and TfR2 depends on the holotransferrin concentration. Under 
conditions of high iron levels, holotransferrin binds to TfR1 and HFE is released, since the 
binding site of holotransferrin overlaps the HFE binding site [69, 70]. As a consequence, HFE 
binds to TfR2 and this complex enhances hepcidin expression [69, 70]. The signaling pathway 
downstream of the HFE/TfR2 complex is still not completely understood but it might involve a 
cross-talk between BMP and mitogen-activated protein kinases (MAPK) signaling pathways [71]. 
Hepcidin regulation by inflammation 
Iron is an essential element for pathogens. As a host defense strategy, hepcidin expression 
increases during inflammation in an attempt to decrease plasma iron availability for extracellular 
pathogens (reviewed in [72]). The inflammatory cytokine interleukin (IL) 6 seems to be a key 
factor that activates hepcidin expression in hepatocytes by triggering the activation of a signaling 
pathway mediated by Janus kinase (JAK) and signal transduction and activator of transcription 
(STAT) 3 [73-75]. Upon the binding of IL6 to its receptor, JAK kinase is activated and 
phosphorylates STAT3, which is then translocated to the nucleus and directly activates hepcidin 
expression by binding to its promoter. Interestingly, the integrity of the BMP signaling pathway is 
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necessary to increase hepcidin expression during inflammation since liver specific SMAD4 
knock out mice fail to increase hepcidin levels upon IL-6 injection [76]. Moreover, a mutation in 
the BMP-responsive element in the hepcidin promoter impairs hepcidin expression in response 
to IL-6 [77]. 
Hepcidin regulation by erythropoietic signals 
Erythropoiesis depends on iron availability since iron is needed for heme and hemoglobin 
synthesis: 20-25 mg of iron are recycled every day for the synthesis of new red blood cells. In 
conditions of high erythropoietic activity, hepcidin expression is downregulated in order to 
increase iron availability. In 2014, erythroferrone (ERFE), a hormone produced by erythroblasts, 
was identified as the erythroid factor responsible for hepcidin repression [78]. ERFE-deficient 
mice do not suppress hepcidin expression after hemorrhage. However, the ERFE receptor and 
ERFE signaling pathway are still not known [78]. Two other factors, growth differentiation factor 
15 (GDF-15) and twisted gastrulation homolog 1 (TWSG1), might also be involved in reducing 
hepcidin expression in conditions of high erythropoietic demand [79, 80]. 
Hepcidin regulation by hypoxia 
Hepcidin expression is inhibited by hypoxia and different mechanisms have been proposed to 
explain this observation. 
The kidney senses systemic hypoxia and responds by producing an erythroid growth factor 
known as erythropoietin (EPO) [81]. The secretion of EPO stimulates erythropoiesis in the bone 
marrow in order to restore a proper delivery of oxygen to every cell type in the organism. EPO is 
likely to suppress hepcidin expression indirectly by stimulating erythropoiesis and therefore 
increasing ERFE [82] (section: “Hepcidin regulation by erythropoietic signals”). 
The heterodimeric hypoxia-inducible factors (HIF-1/HIF- and HIF-2/HIF-) are known to 
regulate the transcription of several iron-related genes, such as Fpn and Dmt1 in enterocytes 
[83, 84], and it was reported that HIFs might directly repress hepcidin promoter activity under 
hypoxic conditions [85]. Under normoxia, the oxygen- and iron-dependent prolyl hydroxylases 
(PHDs) hydroxylate the HIF-1α and HIF-2α subunits, which then associate with the von Hippel-
Lindau tumor suppressor (pVHL). This complex is polyubiquitinated by an E3 ligase and HIFs 
subunits are rapidly degraded. Under hypoxic conditions, the activity of PHDs is reduced due to 
the lack of oxygen and HIF-1α and HIF-2α subunits are no longer hydroxylated and targeted for 
proteasomal degradation (reviewed by [86]). As a consequence, HIF-1α and HIF-2α are stable 
and recruit HIF-β (which is constitutively expressed), forming heterodimers that can directly 
regulate gene expression. 
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However, later studies suggested that hepcidin regulation during hypoxia does not occur via 
direct effects of the pVHL/PHD/HIF axis on the hepcidin promoter but probably through EPO-
mediated erythropoiesis [87, 88]. 
Nevertheless, HIF-1α may indirectly regulate hepcidin expression. A functional hypoxia-
responsive element was identified in the TMPRSS6 promoter region and mutations in this 
element impair HIF1α-dependent induction of TMPRSS6 expression [89]. Similarly, hypoxia also 
increases the expression of furin via HIF-1α [66, 90]. These observations suggest that increased 
expression of TMPRSS6 and furin under hypoxic conditions may be an additional mechanism to 
repress hepcidin expression. 
 
1.5.3  Regulation of ferroportin expression 
As previously mentioned, ferroportin (also known as SLC40A1, Ireg1 and MTP1) is the only 
known cellular iron exporter [9, 10]. The systemic inactivation of the Fpn gene in mice results in 
embryonic lethality [48]. Interestingly, mice in which the Fpn gene was inactivated in all tissues 
except placenta and the extraembryonic visceral endoderm were viable, likely reflecting a 
correct iron transfer from the mother to the embryo [48]. Nevertheless, these animals 
accumulate iron in enterocytes, splenic and liver macrophages, and hepatocytes shortly after 
birth – highlighting the major role of FPN in iron export in these cell types [48]. 
Contrary to hepcidin, FPN expression is regulated at several levels and not only at the 
transcription level. 
Transcriptional regulation of ferroportin 
Heme, a product of hemoglobin degradation, increases Fpn transcription in macrophages. The 
presence of heme induces the degradation of the transcriptional repressor Btb And Cnc 
Homology 1 (Bach1) and allows the transcriptional activator Nuclear Factor Erythroid 2-like 
(Nrf2) to bind to Small Maf proteins (sMAFs) and enhance Fpn transcription [91]. Additionally, 
Fpn transcription is also increased by iron in macrophages [92] but the molecular mechanism 
behind this observation is not known yet. 
It has been reported that Fpn transcription is decreased under inflammatory conditions. Upon 
lipopolysaccharide (LPS) stimulation, Fpn mRNA levels decrease in macrophages from the 
spleen and the liver, probably in an attempt to reduce iron availability for extracellular pathogens 
[93-95]. The molecular mechanism behind Fpn transcriptional repression during inflammation is 
still not completely understood. The stimulation of toll-like receptors (TLR) 2/6 dependent 
signaling pathways by the Mycoplasma–derived molecule FSL1 was shown to repress Fpn 
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transcription [96]. Upon Pseudomonas aeruginosa infection or LPS stimulation, Fpn mRNA 
levels were shown to be reduced in a TLR 4 dependent manner [93, 97]. The direct effect of 
increased inflammatory cytokines such as TNF still remains controversial [93, 98]. 
Hypoxia and iron deficiency were shown to induce Fpn transcription in duodenal enterocytes. In 
these conditions, HIF2-is stabilized, forms a heterodimer with HIF-β, and binds directly to HIF 
response elements present in the promoter of Fpn [83, 84]. Upon binding, the HIF2 heterodimer 
stimulates Fpn expression and therefore increases the export of iron from enterocytes to the 
bloodstream; this ensures an increase in dietary iron absorption in order to counteract the iron 
deficiency or the hypoxia (by increasing the levels of iron available for erythropoiesis). 
Post-transcriptional regulation of ferroportin 
At the post-transcriptional level, FPN is regulated by the IRE/IRP system. As described in 
section 1.4, when intracellular levels of iron are low, IRP1 or 2 bind to the IRE present in the 5’ 
UTR of Fpn mRNA, blocking its translation and therefore decreasing cellular iron export [9, 10]. 
When intracellular iron levels are high, Fpn mRNA is translated and iron export increases. This 
mechanism prevents both toxic intracellular iron overload as well as detrimental intracellular iron 
depletion (reviewed in [31]). 
Interestingly, duodenal enterocytes and erythroid precursors additionally use an alternative 
upstream promoter to express a Fpn transcript with an identical open reading frame but that 
lacks the IRE in the 5’ UTR [99]. These cells can evade translational repression of FPN in 
conditions of low iron levels. As a result, enterocytes can export iron into the plasma under iron 
deficient conditions in order to restore systemic iron levels. This alternative transcript accounts 
for most of the FPN expression in erythroid precursors and allows these cells to export iron in 
conditions of iron deficiency, in order to increase its availability to other tissues in need. 
Post-translational regulation of ferroportin 
As described in section 1.5.1, FPN is regulated post-translationally by hepcidin [49]. The binding 
of hepcidin to FPN, and the subsequent internalization and degradation of the latter, is 
dependent on the fourth extracellular loop of FPN, which contains the amino acid cysteine (C) at 
position 326. A point mutation in this amino acid (Cysteine        Serine) was identified in a family 
presenting an autosomal dominant form of hereditary hemochromatosis, with elevated 
transferrin saturation and iron deposition in hepatocytes, but not in kupffer cells [100]. Additional 
studies, both in vitro and in vivo, showed that this point mutation (C326S) prevents the binding of 
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hepcidin to FPN [101, 102], revealing the critical role of the thiol form of C326 for hepcidin 
binding. 
The exact mechanism underling FPN internalization and degradation has been investigated 
thoroughly in the past years and it is believed that ubiquitination is the key signal for hepcidin-
induced ferroportin endocytosis [50]. 
 
1.6 Iron related disorders 
The study of the molecular mechanisms underlying iron-related disorders in humans has been 
very useful in the understanding of mechanisms regulating systemic and cellular iron 
homeostasis. Most of the iron-related diseases, both from iron overload and from iron deficiency, 
result from disruptions in the hepcidin/FPN regulatory system. 
1.6.1 Iron overload diseases 
Hereditary hemochromatosis (HH) is an iron overload disease characterized by excessive 
dietary iron absorption that results in elevated plasma iron levels, high transferrin saturation, and 
formation of NTBI. The excess of iron accumulates in several organs, e.g. the liver, leading to 
increased oxidative stress, cell damage, and tissue injury. Different forms of HH exist that 
present with different disease severities and result from different mutations. HH type 1, 2A and 3 
are characterized by mutations in the iron-sensing machinery (HFE, HJV or TfR2, respectively) 
that result in inappropriate low or absent levels of hepcidin [103-106]. HH type 2B results from a 
mutation in the hepcidin gene itself [107]. Deficient hepcidin production observed in these 
patients leads to high levels of FPN at the cell membrane, causing an increase in dietary iron 
absorption by duodenal enterocytes and increased iron release from recycling macrophages. 
These four subtypes of HH are recessive forms of the disease. HH type 4 is an autosomal 
dominant form of hemochromatosis that results from “gain of function” mutations in FPN that 
confer resistance to hepcidin binding [100, 108]. As a consequence, ferroportin remains stable 
at the cell membrane independently of hepcidin levels, leading to elevated iron export into the 
circulation. Hepatic cells become iron overloaded whereas splenic macrophages and kupffer 
cells are iron depleted. This rare disorder is also known as non-classical ferroportin disease and 
is the only HH subtype that is associated with high hepcidin levels, since the iron sensing 
machinery still responds to increased systemic iron levels. 
Loss of function mutations in FPN that lead to incorrect targeting of the protein to the plasma 
membrane or the production of an inactive iron exporter result in a disorder known as classical 
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ferroportin disease (reviewed in [109]). Due to the inability to export iron, specialized iron-
exporting cells such as Kupffer cells and splenic macrophages are iron overloaded. As a 
consequence of iron restriction in these cells, patients present normal to low plasma transferrin 
saturation. 
Other iron overload disorders, known as iron-loading anemias, can develop as a consequence 
of an impaired erythropoiesis system. For example, in -thalassemia, the defective production of 
the -globin chain in erythroid precursors leads to the precipitation of excess -chains and 
results in the apoptosis of these cells. The lack of mature red blood cells and diminished oxygen 
transport capacity stimulate EPO production, which in turn stimulates erythropoiesis but fails to 
correct anemia because the precursors undergo apoptosis. High erythropoietic activity 
suppresses hepcidin expression, leading to hyperabsorption of dietary iron and, consequently, to 
systemic iron overload [110, 111]. 
1.6.2  Iron deficiency diseases 
Insufficient dietary iron intake or blood losses can cause iron deficiency that commonly 
manifests as anemia; since erythropoiesis requires large amounts of iron, a depletion of body 
iron levels impairs this process and leads to low hemoglobin levels. 
However, several other iron deficiency disorders result from elevated hepcidin expression. By 
limiting iron availability for erythropoiesis, these diseases are also often associated with anemia. 
Mutations in TMPRSS6 that inactivate its function as a negative regulator of hepcidin production 
result in an autosomal recessive disorder known as familial iron-refractory iron deficiency 
anemia (IRIDA) [112]. Although patients present with severe iron deficiency that should 
suppress hepcidin expression, serum hepcidin levels are abnormally increased, causing 
uncontrolled FPN degradation and preventing iron from being absorbed from diet and released 
from stores. 
Very high levels of hepcidin are also responsible for another iron-deficiency disorder named 
anemia of inflammation or anemia of chronic diseases [113, 114]. The underlying cause of 
elevated hepcidin expression in these diseases is attributed to an excess of inflammatory 
cytokines, such as IL6 (reviewed in [115]). Despite the hypoferremia observed in these patients, 
overproduction of hepcidin inhibits intestinal iron absorption and macrophage iron release. 
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2. Mammalian Respiratory System 
 
The oxidative metabolism of cells requires high amounts of oxygen (O2). Oxygen is transported 
in the bloodstream bound to hemoglobin in erythrocytes and is delivered to every cell type in the 
body. During aerobic cellular respiration, oxygen is consumed and carbon dioxide (CO2) is 
produced and released into the circulation. 
In order to fulfill the cellular oxygen requirements and to excrete the waste CO2, the respiratory 
system has evolved to allow an efficient gas exchange between the atmosphere and the 
bloodstream. Inhaled air travels through a highly branched conducting tract (nose, pharynx, 
larynx, trachea, bronchi, bronchioles) until it reaches the distal lung where most of the gas 
exchange occurs (reviewed in [116] and [117]). In this region, the surface for gas exchange is 
maximized by the septation into innumerous microscopic thin-walled air sacs called alveoli [118] 
(reviewed in [119]). These structures are in close contact to a dense capillary network. 
The alveolar epithelium is composed by two cell types – alveolar epithelial cells type 1 and type 
2 (also known as pneumocytes type 1 and 2) – whereas the conducting airways are lined by an 
epithelium composed of a variety of multi-ciliated and non-ciliated epithelial cells (Figure 1.3) 
(reviewed in [120]). In healthy conditions, alveolar macrophages are the most common cell type 
present within the alveolar space. 
Millions of liters of air inhaled every day do not only provide the necessary oxygen to support life 
but also expose the respiratory system to pathogens and toxic particles. For this reason, multiple 
physical and chemical innate host-defense mechanisms exist within the respiratory tract. Tight 
adhesions between epithelial cells and the presence of mucus and antimicrobial molecules that 
enhance mucociliary clearance are among the most important features of the pulmonary innate 
immunity (reviewed in [121] and [122]). In addition, pulmonary epithelial cells and alveolar 
macrophages can recognize the presence of pathogens and trigger an inflammatory response, if 
necessary. These cells produce cytokines and chemokines and recruit and activate other cells of 
the immune system (reviewed in [121] and [123]). 
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Figure 1.3 – Structure of the mouse airway epithelium. The larger airways (trachea and bronchi) are lining by a 
pseudostratified columnar epithelium mainly composed of ciliated airway epithelial cells, basal cells, few goblet cells 
and Club cells. As the conducting airway branches into smaller airways (bronchioles and bronchio-alveolar duct), the 
epithelium becomes a simple epithelium mainly composed of Club cells, with interspersed ciliated cells. 
Neuroendocrine cells are present in low numbers in the airway epithelium and are commonly found in small clusters 
called neuroepithelial bodies. Alveoli are lined by an uninterrupted epithelium consisting of alveolar epithelial type 1 
and type 2 cells, surrounded by a dense capillary network. Alveolar macrophages are the primary immune cells 
present in the airway lumen of a healthy lung. Image created based on image from Wong et al., 2009 [124]. 
 
2.1   Pulmonary vasculature 
After oxygenation of cells throughout the body, deoxygenated blood is pumped from the right 
ventricle of the heart to the lungs via the main pulmonary artery. This artery divides into the right 
and the left main branches, which transport blood to the four right lobes and the left lobe of the 
mouse lung (reviewed in [125]). Within each lobe, the arteries rapidly subdivide into branches 
that follow the bronchial tree: arteries break into small arteries, followed by arterioles and then 
innumerous capillaries that completely envelop the alveoli (reviewed in [125]). 
Large pulmonary arteries are classified as elastic since their wall is mainly composed by elastic 
fibers and some smooth muscle cells. As they divide and their vascular diameter decreases, the 
composition of their wall changes leading to an increase in the smooth muscle cell layer and a 
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decrease in the elastic fibers – these arteries are classified as muscular arteries [126]. The wall 
thickness of the vessels gradually decreases when they further subdivide: small arterioles are 
surrounded by a non-uniform layer of smooth muscle cells and are followed by smaller non-
muscular arterioles located proximal to the terminal bronchi [127]. At the alveoli region, these 
arterioles give rise to capillaries whose walls consist of a single layer of endothelial cells [128]. 
The thin pulmonary endothelium is ideal for gas exchange to occur: carbon dioxide is released 
and oxygen is taken up. Oxygenated blood travels through the capillaries into venules, which are 
in gross structure similar to arterioles (reviewed in [129]). Venules are distributed irregularly 
within the lung and do not follow the bronchial tree. These vessels come together to form the 
pulmonary veins and transport oxygenated blood to the left atrium of the heart. Oxygen can then 
be delivered to cells throughout the body through the systemic circulation. 
 
2.2 Trachea, bronchi and bronchioles 
The trachea, bronchi and bronchioles form a tree-like system of branched tubes that carries air 
to and from the alveoli. In the mouse lung, the trachea and main bronchi are lined by a 
pseudostratified columnar epithelium whereas the smaller airways are lined by a simple 
columnar epithelium (Figure 1.3) (reviewed in [120]). The epithelium is covered by the airway 
lining fluid, which protects the underlying cells against desiccation and damage, and plays an 
important role in the delivery of almost completely sterile gases to the alveoli. 
Studies throughout the years have revealed a big diversity of cells that form the airway 
epithelium. These cells can be broadly divided into the following groups: 
Ciliated airway epithelial cells: Ciliated epithelial cells are considered terminally differentiated 
cells [130]. They are present in large numbers in the mouse upper airways and each cell 
possesses up to 300 cilia on its apical surface. The coordinated movement of cilia is essential to 
move the mucus along the respiratory tract (see Goblet cells section). Cilia dysfunction impairs 
this process and leads to recurrent respiratory infections [131]. 
Goblet cells: Goblet cells are non-ciliated secretory cells that produce and secret mucin, i.e. 
highly glycosylated proteins that, together with water, form the mucus lining the airway 
epithelium [132] (reviewed in [133]). Inhaled materials/pathogens get trapped in this mucus and 
are subsequently removed from the respiratory system through the highly synchronized beat of 
cilia from ciliated airway epithelial cells, in a process called mucociliary clearance (reviewed in 
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[134]). The importance of the mucus in the healthy lung is highlighted by the observation that 
mice lacking the constitutively produced mucin MUC5b present chronic inflammation [135]. 
Basal cells: In the mouse lung, basal cells are mainly localized between ciliated and secretory 
cells in the larger airways. The abundant cytoskeleton and the presence of desmosomes and 
hemidesmosomes highlight the role of basal cells as major structural components of the 
epithelium, attaching it to the underlying basement membrane [136, 137]. Moreover, basal cells 
have also an important role in the homeostasis of the epithelium since they have the ability to 
self-renew and give rise to secretory and ciliated airway epithelial cells [138, 139]. 
Club cells: Club cells are the main cell type present in mouse small airways. These non-ciliated 
secretory cells produce and secrete several components of the airway lining fluid, such as the 
club cell secretory protein (CCSP) (reviewed in [140]). The study of CCSP-/- mice revealed the 
important role of club cells and their secretions in lung homeostasis: CCSP deficiency is 
associated with atypical airway lining fluid composition, increased susceptibility to lung injury and 
oxidative stress, as well as altered lung inflammatory responses [141-144] (reviewed in [124]). 
Despite being differentiated cells, club cells have the potential to reenter the cell cycle and 
contribute to the renewal of the bronchiolar airway epithelium [145, 146]. 
Pulmonary neuroendocrine cells: Pulmonary neuroendocrine cells (PNEC) are localized within 
the epithelium lining the trachea, bronchi, and bronchioles, and they can be grouped in small 
clusters called neuroepithelial bodies (reviewed in [147]). Even though these are the first 
specialized cells to differentiate in the airway epithelium during development, they are present in 
low numbers in the adult lung. During lung development, PNECs act as modulators of lung 
growth and differentiation (reviewed in [147]); their function in the adult lung is not well known 
yet but they might be involved in airway oxygen sensing [148]. Also, a recent study shows that 
PNECs control lung immune responses by producing neuropeptides [149]. 
 
2.3 Alveoli structure 
Alveoli are lined by an uninterrupted epithelium consisting of alveolar epithelial type 1 and type 2 
cells (AT1 and AT2), which are in close contact with underlying capillaries and fibroblasts (Figure 
1.3) [118] (reviewed in [150]). The alveolar surface is covered by the alveolar lining fluid, which 
protects the underlying epithelial cells against desiccation and pathogens, and facilitates the 
diffusion of gases. 
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AT1 cells are flat and cover >90% of the surface of alveoli [151]. Their high membrane to 
cytoplasm ratio and close apposition to alveolar capillaries create a very thin air-blood barrier, 
essential for a proper gas exchange. These cells are generally regarded as non-proliferative, 
fully differentiated cells [152]. 
AT2 cells are cuboidal-shaped and are often localized in the “corners” of alveoli. Contrary to 
AT1, AT2 cells have the ability to self-renew and differentiate into AT1 cells [153]. AT2 cells 
synthetize, secrete, and recycle the pulmonary surfactant – a mix of extracellular proteins and 
lipids present within the alveolar lining fluid that decreases alveolar surface tension and 
contributes to host defense [154-156]. These cells contain large and abundant secretory 
vesicles called lamellar bodies, which reflect their important secretory function [157]. 
The lung volume does not remain constant during respiration: it increases during inspiration and 
decreases during expiration. By reducing the surface tension at the gaseous-aqueous 
interphase of the alveoli, the surfactant plays an essential role in preventing the collapse of 
alveoli at the end of expiration and reducing the effort needed to expand the lungs during 
inspiration (reviewed in [158]). This way, the surfactant increases lung compliance, i.e. the 
change in lung volume per unit of pressure change, meaning the ease with which the lungs can 
be extended. Inversely, the surfactant decreases lung elastance which is a measure of lung 
stiffness and is defined as the change in the pressure per unit of volume change. 
Even though the exact composition of the surfactant is not completely known yet, it is believed to 
be composed of four surfactant proteins (SP) that account for 10% of the surfactant and by 
several different lipids that comprise 90% of the surfactant layer (reviewed in [158]). The 
hydrophobic SP-B and SP-C have a major role in surfactant structure and function while the 
other two surfactant proteins, SP-A and SP-D, are hydrophilic proteins and contribute to lung 
immunity [159] (reviewed in [156]). They interact with various microorganisms and pathogen-
derived components and act as opsonins by binding and agglutinating pathogens, thus 
enhancing phagocytosis. Moreover, these proteins also directly modulate the activity of alveolar 
macrophages and other immune cells [160, 161] (reviewed in [156]). Consistently, mice deficient 
in SP-D or SP-A are more susceptible to lung inflammation and infection than wild-type mice 
[162-164]. 
AT2 cells play an important role in host defense not only by producing surfactant proteins but 
also by producing cytokines and expressing ligands that regulate the activity of immune cells 
[165-167] (reviewed in [168]). 
Finally, both AT1 and AT2 cells express ion channels and might be involved in alveolar fluid 
homeostasis [169, 170]. 
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The thin air-blood barrier is exposed to two main physical stresses: the pressure within the 
capillaries and the increased longitudinal tension of the alveolar wall when the lung is inflated to 
high volumes (reviewed in [171]). Interstitial fibroblasts play an essential role in supporting the 
alveolar structure by secreting extracellular matrix (ECM). In a healthy lung, fibroblasts 
synthetize small amounts of ECM, enough to preserve the integrity of the alveolar barrier while 
maintaining it as thin as possible. Different pathological conditions that lead to the recruitment 
and activation of fibroblasts, differentiation into myofibroblasts, and increased production of ECM 
contribute for increased lung stiffness and pathology of fibrotic lung diseases [172-174].  
 
2.4 Alveolar Macrophages 
Alveolar macrophages (AMs) are the primary immune cells present in the airway lumen of a 
healthy lung. Due to the techniques used to investigate the biology of these cells, most studies 
do not distinguish between macrophages present within the alveolar space and those present 
within larger airspaces. For this reason, in this thesis, the term “alveolar macrophage” is used to 
describe a mixed population of macrophages that reside in the lumen of the airways. 
Being the first immune cells to contact with inhaled pathogens, AMs are extremely important in 
lung immunological responses. However, they also play an equally important role in clearing 
apoptotic cells, excessive surfactant and cellular debris in health and disease situations 
(reviewed in [123]). 
The unique environment in which AMs exist has a strong influence on their phenotype and 
function, which is illustrated by the observation that peritoneal macrophages acquire expression 
markers of AMs when transferred into the lung [175]. In mice, AMs are phenotypically very 
different from other macrophage populations (reviewed in [123]). They express high levels of 
cluster of differentiation (CD)-11c (also known as integrin x), a molecule that is not typically 
expressed in macrophages but is a typical marker of dendritic cells [175-177]. Similarly, AMs 
express CD205 (also known as DEC-205), which is also expressed by dendritic cells and has 
not been reported to be expressed by macrophages [175, 178]. In contrast, AMs express low 
levels of CD11b, which is typically expressed by other macrophage populations [175, 177]. 
Moreover, mouse AMs express intermediate/low levels of CD14 [176] and high levels of sialic 
acid-binding immunoglobulin-like lectin F (SiglecF), which is mainly expressed by eosinophils 
[176, 179]. 
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Origin and differentiation of alveolar macrophages 
The initial colonization of the airways with AMs is dependent on embryonically derived fetal 
monocytes, which fully differentiate into AMs in the first days after birth [180] (reviewed in [181]). 
Throughout life, AMs have the ability to self-renew and maintain the population with minor 
contribution from circulating monocytes [182]. Even though conflicting studies exist, it is believed 
that circulating monocytes only contribute to AM repopulation when these cells have a limited 
capacity for proliferation, as in the case of radiation-induced depletion of AMs [182]. 
Both differentiation and survival of AMs is highly dependent on the granulocyte-macrophage 
colony-stimulating factor (GM-CSF, also known as CSF2) and possibly also on surfactant 
proteins [175, 180, 182]. The essential role of GM-CSF is highlighted by the observation that 
GM-CSF-/- mice fail to generate mature and fully functional AMs [180]. 
GM-CSF has long been described as a key factor in the proliferation and maturation of myeloid 
lineages (reviewed in [183]) but it has also been reported to act in other biological contexts such 
as proliferation of endothelial progenitor cells and during embryo implantation and development 
[184] (reviewed in [185]). The effects of GM-CSF are mediated through a heterodimeric receptor 
composed of a ligand-specific -subunit (GM-R) and a common -subunit that is also a 
component of IL-3 and IL-5 receptors [186-188]. The GM-Rsubunit binds to GM-CSF with low 
affinity as a monomer but with high affinity when associated with the subunit [187]. Even 
though the GM-R subunit is incapable of binding to GM-CSF as a monomer, it plays an 
important role in GM-CSF-induced signal transduction. The high-affinity complex (GM-R/GM-
R) transduces signals through JAK-STAT-, MAPK-, and phosphatidylinositol 3-Kinase (PI3K)-
dependent pathways to alter the expression of target genes [184, 189-191]. 
Regulatory effects of the lung microenvironment 
Due to their unique position in the airspace, AMs are exposed to air pollutants, pathogens, and 
dust. AMs have to accurately discriminate between situations that require an inflammatory 
response (pathogens) and those that require a tolerogenic response (lung microbiome [192] and 
innocuous stimuli). For this reason, and in order to prevent unwanted inflammatory responses, 
AM activation is negatively regulated via cell-cell interactions with airway epithelial cells 
(reviewed in [123]). For example, the airway epithelium expresses CD200 which interacts with its 
receptor expressed in AMs and inhibits their activation [166]. Additionally, the non-inflammatory 
status of AMs is also maintained by the presence of secreted factors such as surfactant proteins 
(SP-A and SP-D), transforming growth factor TGF- and IL-10 produced by the lung 
epithelium [161, 193, 194] (reviewed in [123]). Hence, a combination of events that overcome 
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the inhibitory stimuli must occur for an inflammatory response to initiate. The presence of 
pathogens in the airways activates TLR-dependent signaling pathways in AMs, releasing them 
from the suppression mediated by epithelial cells and triggering their activation [193]. 
Furthermore, the destruction of the airway epithelium during inflammation leads to the loss of 
negative regulators, such as CD200, enhancing the inflammatory status. 
Once activated, AMs have a high phagocytic capacity and produce high levels of inflammatory 
cytokines and chemotactic factors, which leads to the recruitment of other immune cells, such as 
neutrophils, to the bronchoalveolar space [195-197] (reviewed in [198]). 
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3. Lung iron homeostasis 
Like every other cell type in the body, lung cells take up iron from the bloodstream and use it to 
fulfill their metabolic needs. However, they must also prevent toxic iron overload. In the particular 
case of the lung, the risk of oxidative stress is very high since this organ is exposed to the 
atmosphere and therefore to high levels of oxygen. Moreover, lung cells are not only exposed to 
iron circulating in the blood but also to iron present in inhaled particles - the atmosphere is a 
vehicle for the movement and redistribution of metals, such as iron (reviewed in [199]). Human 
activities have contributed to increased levels of atmospheric iron via the production of air 
pollution particles [200]. Iron is also present in cigarette smoke (a factor with a strong causative 
link to pulmonary pathology) and accumulates in the lung: pulmonary iron levels are higher in 
cigarette smokers when compared with nonsmokers [201]. 
Even though high levels of antioxidants, such as glutathione and ascorbic acid, are present in 
the respiratory tract lining fluid, an imbalance in iron levels in the lung can lead to oxidative 
stress [202] (reviewed in [203]). 
 
3.1 Iron metabolism in the lung 
Contrary to duodenal enterocytes, the lung did not evolve to absorb iron to meet the body 
nutritional requirements. Instead, by being exposed to iron from blood and from inhaled 
particles, the lung has an essential role in iron detoxification (review in [204]). In a healthy lung, 
iron homeostasis is tightly controlled and the availability of free iron is limited. It has been 
suggested that lung cells sequester iron intracellularly bound to ferritin and therefore in a less 
reactive form (review in [204]). In fact, pulmonary ferritin levels increase upon iron exposure 
[204, 205]. 
Several studies showed that lung cells express the same iron-related proteins that are 
expressed in enterocytes and hepatocytes (reviewed in [204]) (Figure 1.4). However, how iron 
homeostasis is maintained in the lung is not completely understood and conflicting data exist 
between different studies. 
Iron uptake by lung epithelial cells: Similar to duodenal enterocytes, lung epithelial cells express 
DMT1 in their apical membrane and take up non-transferrin bound iron from the airway lumen 
(Figure 1.4) [206, 207]. However, it is still not clear how the expression of DMT1 responds to 
increased iron concentrations. Wang et al. observed that the mRNA and protein levels of the 
DMT1 isoform without IRE increase in the airway epithelium in vitro and in vivo upon exposure to 
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iron whereas Giorgi et al. observed that the protein levels of DMT1 in the lung are unchanged in 
mice injected intraperitoneally with iron-saccharate [206, 208]. The uptake of iron via DMT1 
needs to be coupled with the reduction of ferric iron to ferrous iron (described in section 1.3.). 
Turi et al. reported that DcytB is expressed in airway epithelial cells (similar to enterocytes) and 
probably reduces iron before its uptake [209]. 
Giorgi et al. showed that ZIP14 is expressed in airway epithelial cells and that its expression 
increases in conditions of iron overload [208]. Wang et al. reported that Zip14 levels in the lung 
are very low but demonstrated that Zip8 is highly expressed in the lung [46]. For this reason, 
ZIP8 is another candidate for the uptake of non-transferrin bound iron by lung cells. 
Iron export by lung epithelial cells: In the model which proposes that iron is detoxified in the lung, 
airway epithelial cells not only take up and store iron, but are also able to export it in a less 
reactive form via ferroportin or bound to ferritin or transferrin (reviewed in [204]). The authors 
suggested that iron could then be transported out of the lung via the mucociliary pathway or via 
blood to the reticuloendothelial system for long term storage. However, conflicting data exist 
regarding this model. Yang et al. reported that FPN is expressed at the apical membrane of 
airway epithelial cells while Giorgi et al. showed that FPN is expressed in the cytoplasm of these 
cells [208, 210]. On the other hand, the idea that FPN expression increases in lung cells upon 
exposure to iron seems to be consistent in different studies [208, 211]. Taken together, more 
studies are needed to fully understand if lung epithelial cells are able to export iron or not. 
 
Alveolar macrophages: AMs play a key role in lung iron homeostasis. These cells have the 
capacity to sequester large quantities of iron intracellularly bound to ferritin and therefore in a 
less reactive form. AMs from smokers show very high levels of iron and it was suggested that 
this storage prevents oxidative stress by decreasing the generation of extracellular hydroxyl 
radicals [212]. Moreover, AMs from mice injected intraperitoneally with iron-saccharate (which 
present increased pulmonary iron content) show increased iron levels, suggesting that AMs take 
up the excess of iron in conditions of iron overload [208]. 
It was reported that AMs may take up both transferrin and non-transferrin bound iron as they 
express TfR1 and DMT1 [207, 213, 214]. Via phagocytosis, alveolar macrophages can also 
retain iron derived from senescent cells and from inorganic iron-rich dust (reviewed in [215]). 
Whether AMs are able to export iron is currently not clear. It has been suggested that they might 
export it via ferritin or FPN [204], but there is a lack of strong evidence to support this idea. 
Further studies are necessary to confirm or exclude this hypothesis. 
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Hepcidin expression in the lung: Giorgi et al. showed that unlike hepatic hepcidin expression, 
total lung hepcidin levels do not increase in response to iron [208]. Moreover, they suggested 
that hepcidin expression in the lung does not alter iron homeostasis in this organ [208]. Frazier 
et al. studied the expression of hepcidin in human airway epithelial cells in vitro and have come 
to the same conclusion [216]. Contrasting these findings, Chen et al. showed that the silencing 
of hepcidin expression in airway epithelial cells leads to a reduced degradation of FPN in the 
lung in a mouse model of sepsis-induced acute lung injury [217]. They also observed a decrease 
in intracellular iron content of AMs, probably as a consequence of increase FPN protein levels 
[217]. Nguyen et al. reported that AMs also produce hepcidin and that its expression increases 
upon treatment with LPS [214]. However, its role in lung iron homeostasis was not elucidated in 
this study. 
 
3.2 Lung diseases associated with iron overload  
A dysregulation of lung iron homeostasis caused by either endogenous or exogenous factors is 
likely to increase the availability of free iron. Increased iron levels in the lung caused by the 
injection of intravenous iron result in increased oxidative stress [202], which can lead to tissue 
injury and contribute to the pathogenesis of several diseases. In fact, increasing evidence shows 
that several chronic and acute lung diseases are associated with a dysregulation of pulmonary 
iron homeostasis (reviewed in [204]). Patients with idiopathic pulmonary alveolar proteinosis, 
acute respiratory distress syndrome, cystic fibrosis, and chronic obstructive pulmonary disease 
(COPD) show higher levels of iron and iron-related proteins (e.g. ferritin and TfR1) in the lung 
when compared to healthy individuals [218-221]. In most of these studies, iron was detected 
both extracellularly in the bronchoalveolar space and intracellularly. AMs were described as the 
predominant iron loaded cell type and the percentage of iron loaded AMs in patients with COPD 
was correlated with increased disease severity [218]. However, these studies mostly remain on 
the observational level. Whether increased pulmonary iron levels contribute to the development 
of these lung diseases is still poorly understood. 
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Figure 1.4 – Lung iron homeostasis. A model was proposed in which iron is detoxified in the lung. This involves 
the uptake of iron by airway epithelial cells and alveolar macrophages. These cells store iron intracellularly bound to 
ferritin. Airway epithelial cells can take up iron from the airway space via DMT1 (a process coupled with the activity 
of DcytB) and possibly via ZIP14 or ZIP8. It is still not clear if these cells can export iron but several mechanisms 
have been proposed: export of iron via ferroportin (FPN) or bound to transferrin or ferritin. Alveolar macrophages 
take up transferrin and non-transferrin bound iron via TfR1 and DMT1, respectively. It is also not clear if these cells 
can export iron via FPN. 
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4. Research Aims 
The pathogenesis of lung diseases associated with iron overload is poorly understood. It is not 
clear whether the observed increase in lung iron levels contributes to disease onset and 
progression or if it represents a secondary effect resulting from lung injury. 
Some studies have addressed the impact of increased lung iron content by the inhalation of 
particles containing iron [222-224]. However, limited data exist regarding the impact of increased 
circulating iron levels on pulmonary iron content and function. 
The major aim of this work was to understand whether a disruption of the hepcidin/FPN 
regulatory system and the subsequent increase in systemic iron levels affect lung iron 
homeostasis and function. We analyzed a mouse model of hereditary hemochromatosis type 4 
(Slc40a1C326S) which is characterized by a disrupted hepcidin/FPN regulatory circuitry [102]. The 
disruption of the hepcidin/FPN interaction is caused by a missense mutation (C326S) introduced 
into the murine ferroportin gene. This mutation was previously identified in patients [100] and 
was shown to impair the binding of hepcidin to FPN in cellular assays [101]. As a consequence 
of FPN stabilization and uncontrolled iron export, these mice show elevated plasma iron levels, 
hepatic iron overload, and iron depletion in duodenal enterocytes and reticuloendothelial 
macrophages [102]. 
The specific goals of this study were to:  
- understand how the lung iron content and distribution is affected by a disruption of the 
hepcidin/FPN regulatory system and increased systemic iron levels; 
- characterize the expression of iron-related genes in order to dissect the molecular 
mechanisms controlling lung iron homeostasis; 
- identify the (patho)physiological consequences of increased pulmonary iron content in 
terms of lung inflammation and lung function. 
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Mice 
Slc40a1C326S mice analyzed were maintained on a pure C57BL/6N genetic background (>99.9% 
congenic). As controls, age- and gender-matched wild-type C57BL/6N mice born and 
maintained in the same breeding facility were used. Mice were housed in the Heidelberg 
University animal facility under a constant light-dark cycle and maintained on a standard mouse 
diet (LASQCdiet Rod18-A - LASvendi) containing 200 ppm iron with ad libitum access to food 
and water. 
All mouse breeding and animal experiments were approved by the Regierungspräsidium 
Karlsruhe (Projects Nr T-81/14, T-66/13, G-41/16, G-39/16). 
 
Since Hamp-/- mice have a different genetic background (C57BL/6J), wild-type and Slc40a1C326S 
mice with the same genetic background were used for the comparison of lung non-heme iron 
content between these three mouse models. These mice were housed in the EMBL animal 
facility. Mouse breeding and the experiment were approved by and conducted in compliance 
with the guidelines of the EMBL Institutional Animal Care and Use Committee.  
 
Bronchoalveolar lavage and differential cell count 
Mice were anesthetized via intraperitoneal injection of a combination of ketamine (Pfizer) and 
xylazine (Bayer) (120 and 16 mg/kg respectively) and sacrificed by exsanguination. A median 
sternotomy was performed, the trachea cannulated and the left mainstem bronchus ligated and 
the right lung was lavaged with Phosphate Buffered Saline (PBS, Sigma). Bronchoalveolar 
lavage (BAL) samples were centrifuged (5 minutes, 600g, 4°C) and BAL fluid supernatant was 
harvested and stored at -80ºC. Total cell counts were determined using a haemocytometer and 
differential cell counts were determined in cytospin preparations stained with May–Grünwald–
Giemsa (Merck). Alveolar macrophage size was determined in cytospin preparations by 
measuring their surface area using the Analysis B imagine analysis software (Olympus). 
 
Isolation and differentiation of bone marrow-derived macrophages (BMDM) 
Bone marrow cells were flushed from tibia and femur using ice-cold Hank’s balanced salt 
solution (HBSS, Sigma) and filtered through a 70 µm cell strainer (BD biosciences). Cells were 
seeded at a density of 350000 cells/cm2 in RPMI1640-Glutamax medium (Life Technologies) 
supplemented with 10% of heat-inactivated fetal bovine serum (Thermo scientific), 1% 
Penicillin/streptomycin (Gibco) and 10 ng/mL M-CSF (Petrotech) and/or GM-CSF (Petrotech). 
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After 4 days, non-adherent cells were removed by HBSS washing and the medium was replaced 
daily until cell harvesting (6 days after seeding). 
To test the presence of ROS upon acute iron treatment, BMDM differentiated in the presence of 
M-CSF were treated overnight with 75 µM of iron-nitrilotriacetate (FeNTA) before harvesting. 
 
Isolation of splenic macrophages 
Mouse splenic macrophages were magnetically separated from splenic cell suspensions in PBS-
EDTA 2mM using anti-F4/80 biotin antibody and anti-biotin MicroBeads (MACS, Miltenyi Biotec), 
according to manufacturer’s instructions. Briefly, spleens were smashed using a 100 µm cell 
strainer and splenic cell suspensions were subject to ACK lysing buffer (Gibco) to lyse red blood 
cells. The suspensions were then incubated for 30 minutes with anti-F4/80 biotin antibody 
(MACS, Miltenyi Biotec) at 4ºC, washed and incubated for 30 minutes with anti-biotin 
MicroBeads (MACS, Miltenyi Biotec) at 4ºC. After washing, splenic macrophages were isolated 
by magnetic cell sorting using MACS separation columns (Miltenyi Biotec). 
 
RNA Extraction, Reverse transcription and qRT-PCR 
RNA from tissues was isolated using Trizol (Life technologies). RNA from BMDM or splenic 
macrophages was isolated using the RNeasy Plus Mini Kit (Qiagen). Alveolar macrophages 
isolated through bronchoalveolar lavage from 6 mice were pooled and RNA extracted using the 
Arcturus PicoPure RNA Isolation kit (Life technologies). The concentration and purity of the RNA 
was determined by Nanodrop2000 (Thermo Scientific). 
The isolated RNA was reverse transcribed in a 25 µl reaction mixture containing 1 µg (or 0,5 µg) 
of RNA, 0,4 mM dNTPs (Carl Roth GMBH), 100 units of RevertAid H Minus Reverse 
Transcriptase (Thermo Scientific), reaction buffer for RT (Thermo Scientific) and 8 ng/µl random 
oligomers as primers (invitrogen). After denaturating the RNA and primers for 10 minutes at 
70°C, the mix was incubated at 42°C for 90 minutes and then at 70°C for 10 minutes to stop the 
reaction. The cDNA was diluted for subsequent quantitative reverse transcription-PCR (qRT- 
PCR) analysis by adding 475 μl of H20 to cDNA obtained from tissues or 175 µl of H20 to cDNA 
from cells. 
SYBR green qRT-PCR was performed using the StepONE Plus real-time PCR system (Applied 
Biosystems), under the following amplification conditions: 95°C 10 minutes, (95°C 15 seconds, 
60°C 1 minute) × 40 cycles. The primers used are listed in Table 1.1. Relative mRNA expression 
of the gene of interest was normalized to Rpl19 (Ribosomal Protein L19) or Ppia (Peptidylprolyl 
isomerase A) mRNA expression. Results were calculated using the ΔΔCt method [225]. 
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Table 1.1 - SYBR green qRT-PCR primers 
 
 Primer Forward Primer Reverse 
TfR1 CCCATGACGTTGAATTGAACCT GTAGTCTCCACGAGCGGAATA 
Dmt1 IRE AGCTAGGGCATGTGGCACTCT ATGTTGCCACCGCTGGTATC 
Fpn TGTCAGCCTGCTGTTTGCAGGA TCTTGCAGCAACTGTGTCACCG 
HO-1 AGGCTAAGACCGCCTTCCT TGTGTTCCTCTGTCAGCATCA 
Rpl19 AGGCATATGGGCATAGGGAAGAG TTGACCTTCAGGTACAGGCTGTG 
Gm-csf GCATGTAGAGGCCATCAAAGA CGGGTCTGCACACATGTTA 
M-csf GGTGGACTGCCAGTATAGAAAG TCCCATATGTCTCCTTCCATAAA 
Tnf TGCCTATGTCTCAGCCTCTTC GAGGCCATTTGGGAACTTCT 
IL6 GCTACCAAACTGGATATAATCAGGA CCAGGTAGCTATGGTACTCCAGAA 
IL1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
Cd11b TGTCCCTGGCTGTTTCTACTG ATTCTCCTTGCAGTTTTGGTG 
Cd11c TCGTATTTGGCTTCCCAGA CCATCATTAGACACCGTCACAT 
SiglecF GAACTTACCTGGCACTGGTGTT GCTCCACTCTGCAGGACTTT 
Spi-C TCCGCAACCCAAGACTCTTCAA GGGTTCTCTGTGGGTGACATTCC 
Hepcidin ATACCAATGCAGAAGAGAAGG AACAGATACCACACTGGGAA 
Zip8 GCAACAATTTTGCTCCCAAT TCCCTATGGAGATGTTTCTGTG 
Zip14 TGGAACCCTCTACTCCAACG CTGAGGGTTGAAGCCAAAAG 
Ppia ACGGCCGATGACGAGCCCTT TCTCCAGTGCTCAGAGCTCGAAA 
Cd205 CTGAAGGCTGGCACACTTT CGATTCTTTCTATATGGAACACCTT 
Cd14 AAAGAAACTGAAGCCTTTCTCG AGCAACAAGCCAAGCACAC 
Cxcl1 AGACCATGGCTGGGATTCAC CGCGACCATTCTTGAGTGTG 
Cxcl2 CCTGGTTCAGAAAATCATCCA CTTCCGTTGAGGGACAGC 
Ccl2 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAGT 
Ccl3 AGATTCCACGCCAATTCATC GCCGGTTTCTCTTAGTCAGGA 
Ccl4 CTCAGCCCTGATGCTTCTCAC AGAGGGGCAGGAAATCTGAAC 
Ccl20 AACTGGGTGAAAAGGGCTGT GTCCAATTCCATCCCAAAAA 
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Tissue iron quantification 
Tissue non-heme iron content was measured using the bathophenanthroline method and 
calculated against dry weight tissue [226]. Briefly, lung tissue was dried for 3 days at 45°C. Dried 
tissue was weighted and a solution of 10% TCA (Carl Roth), 10% HCl (Merck) was added in the 
proportion of 2μl of solution per 100μg of dried tissue, followed by incubation for 2 days at 65°C 
with mild shaking. After centrifugation at 2500g for 5 minutes to remove cell debris, the 
supernatant was used for iron quantification. A chromogenic solution of 3 M Na-acetate, 0,01% 
bathophenanthrolone-disulfonic acid, 0,1% thioglycolic acid was used and a non-chromogenic 
solution of 3 M Na-acetate, 0,1% thioglycolic acid was used as blank. Absorbance was 
measured in a spectrophotometer at 535 nm. Non-heme iron levels are given as μg of iron per 
gram of dried tissue. 
 
Western blot  
Protein lysates were obtained by homogenizing snap-frozen tissues or bone marrow-derived 
macrophages in RIPA buffer (10 mM Tris-HCl pH8, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 
0,1% SDS) supplemented with protease inhibitors (Roche Diagnostics), as previously described 
[227]. Lysates were incubated for 30 minutes on ice and debris was removed by centrifugation 
at 14500g at 4°C for 10 minutes. Protein concentration was determined using the DC protein 
assay following manufacturer’s instructions (BioRad). 50 μg of protein were subjected to 
western-blot analysis with the antibodies listed in Table 1.2. Briefly, samples were mixed with 4x 
Laemmli buffer (250 mM Tris-HCl pH 6,8, 8% SDS, 40% glycerol, 10% -mercaptoethanol, 
0,08% bromophenol blue) and denaturated by heating at 95°C for 5 min. Samples were not 
denatured for FPN protein analysis. After running the samples on a 12% SDS-PAGE, the 
proteins were transferred to a PVDF membrane using wet transfer method. The membrane was 
blocked with 5% nonfat dry milk in TBS-T buffer (20 mM Tris-HCl pH 7,6, 150mM NaCl, 0,1% 
Tween-20) for 1 hour at room temperature. Primary antibodies were incubated for 1 hour at 
room temperature or overnight at 4°C. After washing the membrane with TBS-T, the membranes 
were incubated with secondary antibodies for 1 hour at room temperature (anti-rabbit IgG, anti-
goat IgG or anti-mouse IgG from Sigma-Aldrich). After washing the membrane with TBS-T, ECL-
Plus substrate (Amersham Biosciences) was used to visualize the immune complexes formed 
on the blot. Western blot images were quantitatively acquired with the Vilber Lourmat Fusion-FX 
Chemiluminescence system (Eberhardzell). β-actin was used as loading control. 
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Table 1.2 - Antibodies used for Western Blot (WB), immunohistochemistry (IHC) and 
immunocytochemistry (ICC) 
 
Antigen Host WB 
dilution 
IHC 
dilution 
ICC 
dilution 
Reference/Supplier 
FPN rabbit 1:500 / 1:200 MTP11-A / Alphadiagnostics 
DMT1 rabbit / 1:100 / Gently provided by Dr. Bruno 
Galy [228] 
FtL goat 1:500 / / sc-14420 / SCBT 
TfR1 mouse 1:1000 / / 136800 / Invitrogen  
-actin mouse 1:5000 / / A1978 / Sigma-Aldrich 
-tubulin IV mouse / 1:500 / MU178-UC / Biogenex 
proSP-C rabbit / 1:5000 / ab28744-50 / Abcam 
    α-SMA rabbit / 1:300 / ab5694 / Abcam 
ZIP8 rabbit  2 µg/ml / / Gently provided by Dr. Mitchell 
Knutson 
Desmin rabbit / 1:100 /  Abcam 
 
Lipid peroxidation - TBARS measurements 
Thiobarbituric acid reactive substances (TBARS) levels were measured in samples of mouse 
total lung using the QuantiChrom TBARS Assay Kit (BioAssay Systems) following 
manufacturer’s instructions. 
 
Iron quantification in the bronchoalveolar lavage fluid supernatant 
BAL fluid supernatant was concentrated through Speed-Vacuum. Iron measurements were 
performed using the SFBC kit (Biolabo) following manufacturer’s instructions. 
 
Measurement of cytokine protein levels in bronchoalveolar lavage fluid 
supernatant 
Cytokine protein levels were determined in BAL fluid supernatant (50 μl) by applying Multiplex 
bead-array based technology. Measurements were performed on a BioPlex200 System using 
the Bio-Plex Pro Cytokine Reagent Kit and Bio-Plex Pro Mouse Cytokine sets (Bio-Rad) 
according to manufacturer’s instructions. Cytokine protein levels are given as picograms (pg) in 
total BAL fluid supernantant. 
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Flow cytometry analysis 
Cells obtained from BAL were stained with CD45.2, CD11c and SiglecF antibodies for 30 
minutes on ice (antibody dilutions and catalog numbers are reported in Table 1.3). To measure 
oxidative stress, BAL cells and BMDM were incubated for 30 minutes at room temperature with 
5 µM CellROX Green reagent (ThermoFisher). After washing, cells were analyzed by flow 
cytometry using the BD LSRFortessa Cell Analyzer. 
 
Table 1.3 - Antibodies used for Flow cytometry 
Antigen Dilution Reference/Supplier 
CD45.2 1/200 109820 / Biolegend 
CD11c 1/200 550261 / BD Pharmingen 
SiglecF 1/200 552126 / BD Pharmingen 
 
Lung Function 
Mice were anesthetized via intraperitoneal injection of Na+-pentobarbital (80 mg/kg), 
tracheostomized and placed on the FlexiVent system (SCIREQ, Montreal, QC, Canada) for 
measurements of pulmonary function. Mice were then paralyzed with pancuronium bromide 
injected intraperitoneally (0,8 mg/kg) to avoid breathing artefacts during the measurement. Mice 
were mechanically ventilated at a frequency of 150 breaths/minute, with a tidal volume of 11 
mL/kg and a positive end expiratory pressure of 3 cm H2O to prevent alveolar collapse. A 
maximum pressure of 30 cm H2O and a maximum volume of 1-2 mL were used to prevent 
hyperinflation of the lung. Pressure-volume curves, total lung capacity, pulmonary compliance 
and elastance were measured as previously described [172, 229]. All perturbations were 
performed until at least three acceptable measurements were reached. Mice were then 
sacrificed by exsanguination. 
 
Blood Oxygen Saturation 
Blood oxygen saturation was determined using a noninvasive pulse oximeter for laboratory 
animals (MouseOx® Plus, Starr life science) following manufacturer’s instructions. Arterial blood 
oxygen saturation was analyzed in conscious mice exposed to room air with a thigh clip sensor. 
The oxygen saturation was measured when pulse waves were stable and regular in order to 
obtain valid values. 
 
 
 Materials and Methods 
35 
 
Immunohistochemistry 
Lungs were inflated with 4% neutral buffered formalin (Fischar) to 25 cm of fixative pressure, 
fixed overnight by immersion in the same solution, dehydrated and paraffin embedded. Lungs 
were sectioned at 1,5 or 5 μm and mounted on Superfrost Plus slides (Thermo scientific). Lung 
sections were rehydrated and treated for 10 minutes with 3% H2O2 (Sigma Aldrich) to block 
endogenous peroxidases. After washing in distilled water, tissue slides were subjected to 
microwave-mediated antigen retrieval using the Citraplus reagent (Biogenex). After 30 minutes 
of cooling, slides were washed 3 times in PBS and subjected to immunorecognition using the 
Vectastain ABC mouse and rabbit kits (Vector Lab, Burlingame, CA, USA) following 
manufacturer’s instructions. Antibody dilutions and catalog numbers are reported in Table 1.2. 
Isotype antibodies were used at the same concentration as the primary antibodies to control for 
antibody specificity. Tissue slides were developed using the Vector AEC substrate (Vector lab), 
rinsed with distilled water, counterstained with Hematoxylin, washed in PBS and mounted using 
the VectaMount AQ mounting medium (Vector lab). Images were digitally acquired with a Nikon 
Ni-E microscope, using the Nikon NIS-Elements software. 
 
Immunocytochemistry 
BAL cells in cytospin preparations were fixed in cold acetone (-20ºC) for 10 minutes, washed in 
PBS and treated for 10 minute with 3% H2O2 (Sigma Aldrich) to block endogenous peroxidases. 
After washing in PBS, slides were subjected to immunorecognition using the Vectastain ABC 
rabbit kit (Vector Lab, Burlingame, CA, USA) following manufacturer’s instructions. FPN antibody 
dilution and catalog number are reported in Table 1.2. An isotype antibody was used at the 
same concentration as the primary antibody to control for antibody specificity. Cytospin 
preparations were developed using the Vector AEC substrate (Vector lab), rinsed with distilled 
water, counterstained with Hematoxylin, washed in PBS and mounted using the VectaMount AQ 
mounting medium (Vector lab). Images were digitally acquired with a Nikon Ni-E microscope, 
using the Nikon NIS-Elements software. Splenic cells in cytospin preparations were subjected to 
the same protocol and used as a positive control for FPN immunocytochemistry. 
 
DAB-enhanced Perls’ stain 
Lungs were inflated with 4% neutral buffered formalin (Fischar) to 25 cm of fixative pressure, 
fixed overnight by immersion in the same solution, dehydrated and paraffin embedded. Lungs 
were sectioned at 1,5 or 5 μm and mounted on Superfrost Plus slides (Thermo scientific). Lung 
sections were rehydrated and stained for 10 minutes with potassium ferrocyanide/HCl solution 
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(Sigma Aldrich). After washing in distilled water, slides were treated with 3,3-
diaminobenzidinetetrahydrochloride (DAB) (Sigma Aldrich). Slides were washed again in distilled 
water, counterstained with Hematoxylin, washed in PBS, dehydrated and mounted using the 
Eukitt quick-hardening mounting medium (Sigma Aldrich). Images were digitally acquired with a 
Nikon Ni-E microscope, using the Nikon NIS-Elements software. 
 
Perls’ stain  
BAL cells in cytospin preparations were stained with potassium ferrocyanide solution/HCl (Sigma 
Aldrich), washed in distilled water and counterstained with Fast Red (Sigma Aldrich). Images 
were digitally acquired with a Nikon Ni-E microscope, using the Nikon NIS-Elements software. 
 
Hematoxylin and eosin stain 
Paraffin lung sections were rehydrated and stained for 6 minutes with Mayer’s Hematoxylin 
(Sigma Aldrich). Slides were washed in water, rinsed in HCl/EtOH, washed again in water and 
stained for 1 minute with Eosin Y (Sigma Aldrich). Slides were dehydrated and mounted using 
the Entellan new mounting medium (Merck). 
 
Masson Goldner Trichrome Stain 
Paraffin lung sections were rehydrated and stained with Masson Goldner Trichrome Staining Kit 
(Carl Roth) following manufacturer’s instructions. 
 
Analysis of lung collagen content 
Paraffin lung sections (3 µm) were stained with 0,1% Sirius red solution as previously described 
[230]. The degree of fibrosis was calculated by the analysis of the total amount of collagen in the 
left lung using a Leica QWin V3 computer assisted image analysis software (Leica Microsystem, 
Wetzlar, Germany). For evaluation of the percentage of collagen, the collagen positive areas 
(red fibers) were determined in a minimum of 300 images per animal. 
 
Stereology of lung tissue  
Lungs from 36 week old mice were instilled via the trachea with 1,5% paraformaldehyde, 1,5% 
glutaraldehyde in 0,15 M Hepes buffer at hydrostatic pressure of 25 cm and stored in the same 
solution at 4°C until further processing. The lungs were embedded in glycol methacrylate 
according to standard protocol [231] and 1,5 µm thick sections were cut. Light microscopy was 
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performed using a Leica DM6000B microscope (Leica, Wetzlar, Germany) attached to a 
computer with the newCAST stereology software (Visiopharm, Horsholm, Denmark). Design-
based stereology was used to quantify the volume of the lung parenchyma and non-parenchyma 
as previously described [231]. 
 
Erythropoietin (EPO) ELISA 
Blood was centrifuged at 2000g for 10 minutes and plasma EPO levels were determined using a 
mouse EPO ELISA kit (R&D systems) following manufacturer’s instructions.  
 
CCL2 ELISA 
Blood was centrifuged at 2000g for 10 minutes and plasma CCL2 levels were determined using 
a mouse CCL2 ELISA kit (R&D systems) following manufacturer’s instructions.  
 
Statistical analyses 
Data are shown as mean ± standard error of the mean (SEM) and the number of mice (n) is 
indicated. Statistical analyses were performed using Prism v6 (GraphPad Software, La Jolla, 
CA). For comparisons between 2 groups, the two-tailed, Student’s t-test was used. For 
comparisons between 3 or 4 groups, a one-way or two-way ANOVA with the Bonferroni post-test 
was used. p-values <0.05 (*), <0.01 (**), <0.001 (***) and <0.0001 (****) are indicated. 
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Increased pulmonary iron content in Slc40a1C326S mice 
  
The Slc40a1C326S mouse model exhibits a phenotype that resembles human hereditary 
hemochromatosis type 4, presenting elevated plasma iron levels, high transferrin saturation, 
parenchymal iron overload, and iron depletion in iron-exporting tissues such as duodenal 
enterocytes and reticuloendothelial macrophages [102]. 
To assess whether a disruption in the hepcidin/FPN regulatory circuitry affects pulmonary 
iron content, lungs from wild-type (Slc40a1wt/wt), heterozygous (Slc40a1wt/C326S) and homozygous 
(Slc40a1C326S/C326S) mutant male and female mice were analyzed at different ages. 
Measurements of non-heme iron levels revealed a genotype-specific and age-dependent 
increase in pulmonary iron content in Slc40a1C326S mice, regardless of the gender (Fig. 2.1A). 
To confirm that the increase in pulmonary iron content observed in Slc40a1C326S/C326S is 
caused by the disruption of the hepcidin/FPN regulatory circuitry and is not a direct 
consequence of the C326S point mutation per se, we compared the lung non-heme iron content 
of Slc40a1C326S/C326S mice and hepcidin knock out (Hamp-/-) mice – both mouse models present a 
disrupted hepcidin/FPN system but result from different genetic mutations. As observed in Fig. 
2.1B, pulmonary iron levels are similar between Slc40a1C326S/C326S and Hamp-/- mice and 
increased when compared to wild-type mice, indicating that the increased lung iron content of 
Slc40a1C326S/C326S mice results from a non-functional hepcidin/FPN system. 
 
Figure 2.1 – Lung iron content of Slc40a1
C326S 
mice 
(A) Total lung non-heme iron levels measured in 10-, 24- and 36-week old male and female mice. 
(B) Total lung non-heme iron levels measured in 50-week old male mice. 
ns – non-significant 
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A molecular analysis of iron-related genes in the lung was performed to evaluate whether 
their expression responds to increased pulmonary iron content. At mRNA level, the expression 
of TfR1 and Dmt1 isoform containing an IRE are decreased in Slc40a1wt/C326S and 
Slc40a1C326S/C326S mice (Fig. 2.2A, B). TfR1 is decreased also at the protein level and correlates 
with an increase in FtL protein levels (Fig. 2.2C). FPN shows a genotype-specific upregulation 
both at mRNA and protein levels (Fig. 2.2C, D). 
 
Figure 2.2 – Expression of iron-related genes in the lung of Slc40a1
C326S 
mice  
(A) qRT-PCR analysis of TfR1 mRNA expression in total lung of 36-week old female mice. 
(B) qRT-PCR analysis of Dmt1 IRE mRNA expression in total lung of 36-week old female mice. 
(C) Western blot analysis of TfR1 (~100 kDa), FtL (~20 kDa), and FPN (~65 kDa) protein expression in total lung 
of 36-week old female mice. -actin (42 kDa) was used as loading control. 
(D) qRT-PCR analysis of Fpn mRNA expression in total lung of 36-week old female mice.  
 
We have also analyzed the expression of two recently identified iron transporters: ZIP8 
and ZIP14, which were reported to mediate the uptake of NTBI [232]. We observed that Zip8 is 
highly expressed in the lung compared to the liver (Fig. 2.3A), an observation that supports a 
study by Wang and colleagues [46]. The same group has shown that ZIP8 protein levels 
increase in response to iron loading due to a post-transcriptional mechanism, without alterations 
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at the mRNA level [46]. Consistently, we did not detect differences in pulmonary Zip8 mRNA 
levels between wild-type and Slc40a1C326S mice (Fig. 2.3A, B). However, we also did not observe 
an increase in ZIP8 protein levels in the lung of Slc40a1C326S mice (Fig. 2.3C). Like ZIP8, ZIP14 
expression is up-regulated by iron in a post-transcriptional manner [45]. In agreement, we did 
not detect differences in Zip14 mRNA levels in the lung of Slc40a1C326S/C326S mice when 
compared with wild-type controls (Fig. 2.3D). Unfortunately, we failed to detect ZIP14 protein in 
lung lysates by Western blot analysis (data not shown). 
 
Figure 2.3 – Expression of Zip8 and Zip14 in wild-type and Slc40a1
C326S 
mice. 
(A) qRT-PCR analysis of Zip8 mRNA expression in total lung and liver of 36-week old female mice. 
(B) qRT-PCR analysis of Zip8 mRNA expression in total lung of 36-week old male and female mice. 
(C) Western blot analysis of ZIP8 (~150 kDa) protein expression in total lung of 36-week old female mice. -actin 
(42 kDa) was used as loading control. 
(D) qRT-PCR analysis of Zip14 mRNA expression in total lung of 36-week old male and female mice. 
ns – non-significant 
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Hepcidin expression in the liver of Slc40a1C326S/C326S mice increases in response to 
increased iron levels [102] (Fig. 2.4). We have analyzed its expression in the lung and have 
detected extremely low hepcidin mRNA levels in this organ compared to the liver (Fig. 2.4). 
Moreover, lung hepcidin levels do not respond to increased pulmonary iron content as no 
differences were observed between wild-type and Slc40a1C326S/C326S mice (Fig. 2.4). 
 
Figure 2.4 – Hepcidin expression in the lung and liver of wild-type and Slc40a1
C326S/C326S
 mice 
qRT-PCR analysis of hepcidin mRNA expression in total lung and total liver of 36-week old female mice. 
ns – non-significant 
 
Excess of iron can lead to the generation of reactive oxygen species (ROS), which cause 
deleterious effects by damaging proteins, lipids, and DNA [102, 233]. Increased iron levels in the 
lung of Slc40a1C326S/C326S mice are associated with increased HO-1 expression, a marker of 
oxidative stress, and with increased lipid peroxidation, as shown by an increase in thiobarbituric 
acid reactive substances (TBARS) (Fig. 2.5). 
 
Figure 2.5 – Markers of oxidative stress in the lung of Slc40a1
C326S mice. 
(A) qRT-PCR analysis of HO-1 mRNA expression in total lung of 36-week old female mice. 
(B) Lipid peroxidation measured through the TBARS assay in total lung of 36-week old female mice.  
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Iron accumulation in the lung of Slc40a1C326S mice is restricted to specific 
cell types 
 
 Histological analysis of the lung of Slc40a1C326S mice confirmed the iron overload 
phenotype (Fig. 2.6). Furthermore, it revealed that iron does not accumulate uniformly in all lung 
cell types but it is instead restricted to specific sub-sets of the lung cell population (Fig. 2.6). 
 
Figure 2.6 – Iron accumulation in the lung of Slc40a1
C326S
 mice is restricted to specific cell types 
DAB-enhanced Perls’ stain of lung sections of 36-week old female mice. The arrow shows an alveolar 
macrophage with strong iron accumulation. 
  
It has been previously proposed that airway epithelial cells can take up iron from the 
airway lumen via DMT1 [204]. Using -tubulin IV as a marker of cilia, we detected DMT1 mainly 
at the apical membrane of ciliated airway epithelial cells in wild-type mice (Fig. 2.7A). In line with 
this observation, iron was frequently detected in ciliated epithelial cells lining the conducting 
airways of Slc40a1C326S/C326S mice (Fig. 2.7B, C). 
 
Iron deposition was occasionally detected in another epithelial cell type – alveolar type 2 
cells (Fig. 2.8). These secretory cells are present in the alveolar epithelium and can be identified 
by the expression of the prosurfactant protein C. 
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Figure 2.7 – Iron accumulation in ciliated airway epithelial cells of Slc40a1
C326S/C326S
 mice. 
(A) Immunohistochemistry for DMT1 (left) and β-tubulin IV (right) of consecutive lung sections from 36-week old 
female wild-type mice. 
(B) DAB-enhanced Perls’ stain (left) and immunohistochemistry for β-tubulin IV (right) of consecutive lung sections 
from 26-week old female Slc40a1
C326S/C326S
 mice. 
(C) Higher magnification of DAB-enhanced Perls’ stain (left) and immunohistochemistry for β-tubulin IV (right) of 
consecutive lung sections from 26-week old female Slc40a1
C326S/C326S
 mice. 
 
 
 
Figure 2.8 – Iron accumulation in alveolar type 2 cells of Slc40a1
C326S/C326S
 mice. 
DAB-enhanced Perls’ stain (left) and immunohistochemistry for prosurfactant protein C (proSP-C, right) of 
consecutive lung sections from 36-week old female Slc40a1
C326S/C326S
 mice. 
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In addition, we detected iron accumulation in vascular smooth muscle cells (SMC) in the 
lung of Slc40a1C326S/C326S mice, which were identified by the expression of alpha smooth muscle 
actin (αSMA) (Fig. 2.9A). However, we have also detected iron-spared vascular SMCs (Fig. 
2.9B), suggesting that the lung contains different populations of vascular SMCs in regard to iron 
trafficking. Interestingly, iron accumulates in vascular SMCs that express low levels of desmin 
whereas vascular SMCs expressing high levels of desmin are iron-spared (Fig. 2.10A). The 
disparity in desmin expression between different vascular SMCs is not a consequence of the 
C326S point mutation and/or alterations in iron levels since a differential expression of desmin 
between different vascular SMCs was also observed in wild-type mice (Fig. 2.10B). 
 
 
Figure 2.9 – Iron accumulation in lung vascular smooth muscle cells of Slc40a1
C326S/C326S
 mice. 
(A) DAB-enhanced Perls’ stain (left and center) and immunohistochemistry for alpha smooth muscle actin (αSMA) 
(right) of consecutive lung sections from 36-week old female Slc40a1
C326S/C326S
 mice. 
(B) DAB-enhanced Perls’ stain (left) and immunohistochemistry for alpha smooth muscle actin (αSMA; right) of 
consecutive lung sections from 36-week old female Slc40a1
C326S/C326S
 mice. 
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Figure 2.10 – Iron accumulates differently in functionally distinct vascular smooth muscle cells. 
(A) DAB-enhanced Perls’ stain (left) and immunohistochemistry for desmin (right) of consecutive lung sections 
from 36-week old female Slc40a1
C326S/C326S
 mice. Arrows indicate vascular SMCs. 
(B) Immunohistochemistry for desmin of lung sections from 36-week old female wild-type mice. 
 
 
 
 
 
 
 
Results 
47 
 
It is important to mention that increased iron levels were also detected extracellularly in 
the bronchoalveolar lavage (BAL) fluid of Slc40a1C326S mice (Fig. 2.11). 
 
 
Figure 2.11 – Iron accumulates extracellularly in the bronchoalveolar space of Slc40a1
C326S/C326S
 mice. 
 Iron levels measured in the bronchoalveolar lavage (BAL) fluid supernatant of 10-, 26- and 36-week old mice. 
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Iron loaded alveolar macrophages in Slc40a1C326S mice 
 
Iron deposition in alveolar macrophages (AM) has been observed in different lung 
diseases [218, 219]. Interestingly, histological analysis of lung sections from Slc40a1C326S/C326S 
mice revealed the presence of strongly iron loaded AMs (Fig. 2.6 arrow). To further confirm this 
observation, we analyzed the cellular fraction of the BAL. Differential May-Grünwald-Giemsa 
stain of cytospin preparations showed that AMs were the predominant cell type in the BAL fluid 
of wild-type and Slc40a1C326S/C326S mice (Fig. 2.12A, B). This analysis further revealed that the 
total number of cells in the BAL fluid of Slc40a1C326S/C326S mice was increased when compared to 
wild-type animals, mainly due to an increase in the number of AMs (Fig. 2.12B). The identity of 
AMs was additionally confirmed by flow cytometry (gating strategy Fig. 2.12C) – more than 90% 
of the immune cells in the BAL fluid of both wild-type and Slc40a1C326S/C326S mice corresponded 
to AMs (CD45.2+ CD11c+ SiglecF+) (Fig. 2.12D) [176]. 
The increase in the number of AMs can result either from proliferation of a progenitor 
population within the lung or from recruitment of circulating monocytes (reviewed in [123]). 
Interestingly, the plasma levels of CCL2 in Slc40a1C326S/C326S mice have a strong tendency to be 
increased (p-value = 0,06), which may directly contribute to the recruitment of monocytes and, 
as a consequence, to an increase in the number of macrophages (Fig. 2.13A). We further 
analyzed the mRNA levels of different chemokines in the lung of Slc40a1C326S/C326S mice. The 
mRNA levels of C-C motif chemokine ligand (Ccl) 2, Ccl3, Ccl4, Ccl20 and C-X-C motif 
chemokine ligand (Cxcl) 2 were not significantly up-regulated in the lung of Slc40a1C326S/C326S 
mice but we observed a small increase in the expression levels of Cxcl1 (Fig. 2.13B-G). We 
have also analyzed the expression levels of two cytokines involved in macrophage 
differentiation: macrophage colony-stimulating factor (M-csf), which was decreased in the lung of 
Slc40a1C326S/C326S mice, and granulocyte macrophage colony-stimulating factor (Gm-csf), which 
showed a robust increase (Fig. 2.13H, I). The increase in Gm-csf mRNA levels is of particular 
interest as this cytokine is a key player in the differentiation of AMs. Additional studies will be 
necessary to understand the underlying mechanism causing the increase in the number of AMs 
in Slc40a1C326S/C326S mice. 
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Figure 2.12 – Alveolar macrophages in the bronchoalveolar space of Slc40a1
C326S/C326S
 mice 
(A) May-Grünwald-Giemsa stain of cytospin preparations obtained from the bronchoalveolar lavage of 26-week old 
male mice. 
(B) Total cell count and differential cell count of the cell fractions of the bronchoalveolar lavage of 26-week old 
male mice. 
(C) Gating strategy used to identify the cells present in the bronchoalveolar lavage fluid of wild-type and 
Slc40a1
C326S/C326S
 mice. 
(D) Percentage of AM (CD11c
+
 Siglec
+
) present in the leukocyte fraction (CD45.2
+
) in the bronchoalveolar lavage 
fluid of 24-week old male mice (n=3). 
ns – non-significant 
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Figure 2.13 – Expression of cytokines in Slc40a1
C326S/C326S
 mice 
(A) CCL2 protein levels measured in the plasma of 13-week old mice. 
(B-I) qRT-PCR analysis of Ccl2 (B), Ccl3 (C), Ccl4 (D), Ccl20 (E), Cxcl2 (F), Cxcl1 (G), M-csf (H) and Gm-csf (I) 
mRNA expression in total lung of female mice. 
ns – non-significant 
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The presence of iron-loaded AMs in Slc40a1C326S/C326S mice was confirmed by Perls’ stain 
on cytospin preparations of BAL cells (Fig. 2.14A). Intracellular iron accumulation in AMs 
distinguishes them from hepatic Kupffer cells and splenic macrophages in Slc40a1C326S/C326S 
mice: these cells are iron depleted due to uncontrolled iron export caused by the resistance of 
FPN to hepcidin binding [102]. Curiously, we also detected iron spared AMs in BAL cytospin 
preparations from Slc40a1C326S/C326S mice (Fig. 2.14A arrow). This finding indicates that the 
population of AMs in Slc40a1C326S/C326S mice is heterogeneous regarding iron handling. This 
heterogeneity in iron accumulation correlates with a heterogeneous expression of FPN in AMs 
from Slc40a1C326S/C326S mice, probably explaining the phenotype (Fig. 2.14B). Interestingly, we 
could not detect FPN in AMs from wild-type mice (Fig. 2.14B). 
 
 
 
 
Figure 2.14 – Iron loaded alveolar macrophages in Slc40a1
C326S/C326S
 mice 
(A) Perls’ stain of cytospin preparations of cells isolated from the bronchoalveolar lavage fluid of 24-week old male 
mice. Arrow shows an iron spared alveolar macrophage. 
(B) Immunocytochemistry for FPN in cytospin preparations of cells isolated from the bronchoalveolar lavage fluid 
of 24-week old male mice. 
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To further confirm the absence of FPN expression in AMs isolated from wild-type mice, 
we analyzed the mRNA levels of Fpn in these cells. To this end, we compared AMs, which were 
isolated from the bronchoalveolar lavage and identified by the expression of high levels of the 
AM markers Cd11c and SiglecF, to splenic macrophages, which were isolated through magnetic 
cell sorting and identified by the expression of high levels of the markers Cd11b and Spi-C (Fig. 
2.15A-D). We observed that AMs express very low levels of Fpn mRNA in comparison to splenic 
macrophages (Fig. 2.15E). 
 
Figure 2.15 – Comparison between alveolar macrophages and splenic macrophages isolated from wild-
type mice 
qRT-PCR analysis of Cd11c (A), SiglecF (B), Cd11b (C), Spi-C (D), and Fpn (E) mRNA expression in 
alveolar macrophages and splenic macrophages isolated from 12-week old wild-type mice. 
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Ferroportin transcription is regulated by different mechanisms, which mostly depend on 
the cell type. For example, ferroportin transcription in duodenal enterocytes is mainly regulated 
by hypoxia [84] while reticuloendothelial macrophages control ferroportin expression via a heme-
dependent pathway [91]. How ferroportin expression is regulated in AMs is still unknown. 
GM-CSF is a key regulator of the differentiation of AMs: GM-CSF-/- mice fail to generate 
mature and functional AMs [180]. Interestingly, GM-CSF was reported to repress FPN 
expression in monocyte-derived macrophages after stressed erythrocyte challenge [234]. Since 
GM-CSF is highly expressed in the lung compared to the spleen (Fig. 2.16A), where 
macrophages express FPN, it is possible that GM-CSF represses ferroportin expression in AMs. 
To test this hypothesis, we differentiated bone marrow hematopoietic progenitors in vitro 
in the presence of GM-CSF and compared them to bone marrow hematopoietic progenitors 
differentiated in the presence of M-CSF – cytokine that is commonly used to differentiate bone 
marrow-derived macrophages (BMDM) in vitro. We observed that BMDM differentiated in the 
presence of GM-CSF upregulate the expression of AMs markers SiglecF, Cd11c, and Cd205 
(Fig. 2.16B-D) [123, 175, 176]. Moreover, the presence of GM-CSF leads to a downregulation of 
Cd14, which is also expressed at intermediate/low levels in AMs (Fig. 2.16E) [123, 176]. These 
observations indicate that BMDM differentiated in the presence of GM-CSF present an AM-like 
phenotype, supporting the major role of GM-CSF in the differentiation of AMs in the lung. 
However, AMs express low levels of Cd11b [176] (Fig. 2.15C), but its expression is not reduced 
in BMDM differentiated in the presence of GM-CSF (Fig. 2.16F), suggesting that other factors 
present within the alveolar microenvironment might be necessary to fully differentiate AMs. 
We observed that in the presence of GM-CSF, the expression of FPN is downregulated 
both at mRNA and protein level when compared to BMDMs differentiated in the presence of M-
CSF (Fig. 2.16G, H). The effect of GM-CSF is dominant, since it is able to downregulate Fpn 
expression also in the presence of M-CSF (Fig. 2.16I). These observations support our 
hypothesis that GM-CSF may mediate the suppression of ferroportin expression in AMs. 
However, we observed AMs expressing FPN in Slc40a1C326S/C326S mice. These FPN+ AMs 
might correspond to recruited macrophages that do not respond to the pulmonary GM-CSF or 
AMs that are still undergoing the differentiation process. 
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Figure 2.16 – GM-CSF represses FPN expression in BMDM 
(A) qRT-PCR analysis of Gm-csf mRNA expression in total lung and total spleen of adult wild-type mice. 
(B-G) qRT-PCR analysis of SiglecF (B), Cd11c (C), Cd205 (D), Cd14 (E) , Cd11b (F) and Fpn (G) mRNA 
expression in wild-type BMDMs differentiated during 6 days in the presence of M-CSF or GM-CSF. 
(H) Western Blot analysis of FPN (~65 kDa) protein expression in wild-type BMDM differentiated during 6 days in 
the presence of M-CSF or GM-CSF. -actin (42 kDa) was used as loading control. 
(I) qRT-PCR analysis of Fpn mRNA expression in wild-type BMDM differentiated during 6 days in the presence of 
M-CSF or M-CSF + GM-CSF.  
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Both phenotype and function of macrophages are shaped by the environment to which 
these cells are exposed (reviewed in [235]). Several studies have described that iron overload in 
macrophages results in oxidative stress, which triggers a switch towards a pro-inflammatory 
state [236-238]. Since we detected iron overloaded AMs in Slc40a1C326S/C326S mice (Fig. 2.14A), 
we analyzed the degree of oxidative stress in these cells as well as the pulmonary inflammatory 
status of Slc40a1C326S/C326S mice. Lung inflammation is hallmarked by an increased expression of 
pro-inflammatory cytokines and a recruitment of immune cells into the bronchoalveolar 
compartment. 
Using the CellRox green as ROS reporter (a fluorogenic probe, which exhibits a strong 
fluorescence upon oxidation by ROS), we did not detect differences in oxidative stress in AMs 
between wild-type and Slc40a1C326S/C326S mice (Fig. 2.17A). In contrast, acute iron treatment of 
BMDM causes the formation of ROS (Fig. 2.17B).  
Despite the increase in the number of AMs (Fig. 2.12B), but consistent with the absence 
of oxidative stress in these cells (Fig. 2.17A), AMs in Slc40a1C326S/C326S mice do not seem to be 
morphologically activated as no significant difference in cell size was observed when compared 
with wild-type AMs (Fig. 2.17C). In agreement, we did not detect an increase in mRNA and 
protein levels of pro-inflammatory cytokines IL1β, IL6, and TNFα in total lung or in the BAL fluid 
supernatant, respectively (Fig. 2.17D, E). Since inflammatory responses are regulated by 
complex networks involving different cell types and the production of different cytokines, we 
further analyzed the expression levels of the anti-inflammatory cytokines IL10 and IL13. We 
failed to detect differences in the protein levels of these cytokines between wild-type and 
Slc40a1C326S/C326S mice (Fig. 2.18). 
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Figure 2.17 – Slc40a1
C326S/C326S
 mice do not show signs of pulmonary inflammation 
(A) FACS analysis of the CellROX oxidative stress tracer of AMs isolated from the BAL of 24-week old male mice. 
(B) FACS analysis of the CellROX oxidative stress tracer of iron-treated BMDM. 
(C) Area of alveolar macrophages isolated from the bronchoalveolar lavage of 36-week old female mice. 
(D) qRT-PCR analysis of IL1β, IL6 and Tnfα mRNA expression in total lung from 36-week old female mice. 
(E) Luminex analysis of IL1β, IL6 and TNFα protein levels in the bronchoalveolar lavage fluid supernatant of 36-
week old female mice. 
ns – non-significant , pg – picograms   
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Figure 2.18 – Expression of anti-inflammatory cytokines in the lung of Slc40a1
C326S/C326S
 mice 
Luminex analysis of IL10 and IL13 protein levels in the bronchoalveolar lavage fluid supernatant of 36-week old 
female mice. 
ns – non-significant , pg – picograms   
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Slc40a1C326S/C326S mice present classical signs of restrictive lung disease 
 
Increased iron levels and consequent increase in oxidative stress are known to cause 
cellular damage and tissue injury [2, 102, 233]. We next investigated whether aged 
Slc40a1C326S/C326S mice present alterations in lung function. 
Measurements of lung function were performed in tracheostomised anaesthetized mice 
using a lung function measurement device for small animals (FlexiVent of Scireq, Canada). This 
analysis revealed classical signs of restrictive lung disease in Slc40a1C326S/C326S mice, such as a 
decrease in total lung capacity and a decrease in pulmonary compliance, which reflects a 
decrease in lung elasticity (Fig. 2.19A, B). Consistently, Slc40a1C326S/C326S mice showed an 
increase in pulmonary elastance, a measurement of lung rigidity (Fig. 2.19C). This finding was 
further confirmed by exposing the mice to fixed air pressures. As shown in the pressure-volume 
curve, an increase in the applied pressure correlated with an increase in lung volume but to a 
lesser extent in Slc40a1C326S/C326S mice when compared to wild-type mice (Fig. 2.19D). 
We excluded the possibility that the observed differences between wild-type and 
Slc40a1C326S/C326S mice were due to differences in body size. Despite the fact that aged 
Slc40a1C326S/C326S mice present a lower body weight, most likely due to exocrine pancreatic 
failure [102], the tibia length (a marker of body size) was comparable to age-matched wild-type 
animals, indicating that both groups of mice have a similar size (Fig. 2.19E, F). 
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Figure 2.19 – Lung function measurements and stereological analysis of the lung of Slc40a1
C326S/C326S
 
mice  
(A-D) Lung function measurements performed in 36-week old female mice. A) Total Lung Capacity; (B) Pulmonary 
Dynamic Compliance; C) Pulmonary Elastance; D) Pressure-Volume (PV) curve with controlled pressure applied. 
(E) Body weight of 10-, 26- and 34-week old female mice. 
(F) Tibia size of 10-, 26- and 34-week old female mice. 
(G) Volume of lung parenchyma measured in 36-week old female mice. 
(H) Volume of lung non-parenchyma measured in 36-week old female mice. 
ns – non-significant 
Results 
60 
 
Together with Prof. Christian Mühlfeld and Dr. Christina Brandenberger (Hannover 
Medical School), we performed a stereological analysis of the lung of Slc40a1C326S/C326S mice, as 
previously described [231]. We applied a grid on images of lung sections obtained by light 
microscopy and counted the number of points overlapping with the alveolar septa (P(alvsept)), 
alveolar airspace (P(alvair)) and alveolar duct airspace (P(ductair)), which together correspond 
to points overlapping the lung parenchyma. We have also counted the points overlapping with 
the lung non-parenchyma (P(non parenchyma)), e.g. conducting airways and blood vessels. We 
estimated the volume fraction (Vv) of the lung parenchyma and lung non-parenchyma as 
following: 
 
𝑉𝑣 (
𝑝𝑎𝑟𝑒𝑛𝑐ℎ𝑦𝑚𝑎
𝑙𝑢𝑛𝑔
) =
[𝑃(𝑑𝑢𝑐𝑡𝑎𝑖𝑟) + 𝑃(𝑎𝑙𝑣𝑠𝑒𝑝𝑡) + 𝑃(𝑎𝑙𝑣𝑎𝑖𝑟)]
𝑃(𝑙𝑢𝑛𝑔)
 
 
 
𝑉𝑣 (
𝑛𝑜𝑛 𝑝𝑎𝑟𝑒𝑛𝑐ℎ𝑦𝑚𝑎
𝑙𝑢𝑛𝑔
) =
𝑃(𝑛𝑜𝑛 𝑝𝑎𝑟𝑒𝑛𝑐ℎ𝑦𝑚𝑎)
𝑃(𝑙𝑢𝑛𝑔)
 
 
𝑃(𝑙𝑢𝑛𝑔) − sum of points overlapping the lung parenchyma and the lung non-parenchyma. 
 
By multiplying the volume fraction of these compartments by the total volume of the lung 
(assessed by the fluid displacement method), we calculated the total volume of the lung 
parenchyma and the total volume of the lung non-parenchyma [231]. This analysis revealed a 
reduction in the volume of the lung parenchyma in Slc40a1C326S/C326S mice, without alterations in 
the volume of the lung non-parenchyma (Fig. 2.19G, H). These observations support the 
restrictive pattern observed by measurements of lung function and indicate that the decrease in 
total lung capacity results from a reduction in the volume of the lung parenchyma. 
A pulmonary restrictive pattern is commonly associated with conditions that increase lung 
stiffness, such as an increase in collagen deposition [172]. However, a marked replacement of 
normal lung parenchyma by fibrotic tissue was not observed (Fig. 2.20). 
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Figure 2.20 – The lung structure in Slc40a1
C326S/C326S
 mice is unaltered compared to wild-type mice. 
(A) Hematoxylin & Eosin stain of lung sections from 36-week old female mice. 
(B) Goldner Masson Trichrome stain of lung sections from 36-week old mice. 
(C) Sirius red stain of lung sections from 36-week old mice. 
(D) Collagen content calculated on Sirius Red stained lung sections from 34-week old mice. 
Quantification of lung collagen deposition was performed by our collaborators Dr. Simone Kraut and Prof. Dr. 
Norbert Weissmann. 
ns – non-significant 
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Slc40a1C326S/C326S mice show decreased blood oxygen saturation 
 
The respiratory system has evolved to maximize the gas exchange between the 
bloodstream and the atmosphere. We observed a strong reduction in blood oxygen saturation in 
aged Slc40a1C326S/C326S mice when compared to wild-type mice (Fig. 2.21A) suggesting that the 
gas exchange in the lung might be compromised. In adult mammals, the kidney is responsible 
for sensing systemic hypoxia and producing the erythroid growth factor erythropoietin (EPO). In 
agreement with the observed decrease in blood oxygen saturation, plasma EPO levels were 
increased in Slc40a1C326S/C326S mice (Fig. 2.21B). Increased levels of circulating EPO stimulate 
erythropoiesis in the bone marrow in order to increase the number of circulating red blood cells 
and improve the delivery of oxygen to every cell in the organism. Consistently, we observed 
higher levels of red blood cells, hemoglobin and hematocrit in Slc40a1C326S/C326S mice (Table 2.1) 
[102]. 
 
Figure 2.21 – Blood oxygen saturation measurement in Slc40a1
C326S/C326S
 mice  
(A) Blood oxygen measurements performed in 36-week old female mice. 
(B) EPO levels measured in the plasma of 36-week old female mice. 
 
Table 2.1 – Hematological parameters in 36-week old mice (n=4) 
Parameter wt/wt C326S/C326S p-value 
Hemoglobin (g/dl) 16,36 ± 0,06 17,66 ± 0,41 * 0,0199 
Hematocrit (%) 53,22 ± 0,53 56,73 ± 1,12 * 0,0296 
Red blood cells (106/µL) 10,60 ± 0,09 11,47 ± 0,05 *** 0,0002 
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Imbalances in iron homeostasis have been reported in a spectrum of lung diseases [204, 219]. 
However, the role of iron in lung pathology is poorly understood. In this work, we aim at 
understanding whether a disruption in the hepcidin/ferroportin regulatory circuitry and the 
subsequent increase in systemic iron levels affect lung iron homeostasis and function.  
Here we show that resistance of ferroportin to hepcidin binding causes an age-dependent 
pulmonary iron deposition in defined lung cell types (Fig. 3.1).  Increased iron levels in this organ 
correlated with increased lipid peroxidation, suggesting that iron-mediated oxidative stress may 
contribute to the pathogenesis of lung diseases. Homozygous Slc40a1C326S/C326S mice show 
classical signs of restrictive lung disease and a significant decrease in blood oxygen saturation. 
These findings implicate iron overload in lung pathology, which has to date not been considered 
a classical iron-related disorder.  
 
Figure 3.1 – Lung iron accumulation and pathophysiological consequences of pulmonary iron overload 
in Slc40a1
C326S/C326S
 mice 
Iron accumulates in specific cell types of the lung of Slc40a1
C326S/C326S
 mice: ciliated airway epithelial cells, 
vascular smooth muscle cells, alveolar type 2 cells and alveolar macrophages. Iron was also detected extracellularly 
in the bronchoalveolar space. Although there is an increase in the number of alveolar macrophages, 
Slc40a1
C326S/C326S
 mice do not show strong signs of pulmonary inflammation. Slc40a1
C326S/C326S
 mice show a 
pulmonary restrictive pattern and decreased blood oxygen saturation. 
FPN – Ferroportin; Fe – iron; sO2 – blood oxygen saturation. 
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Slc40a1C326S mice show increased iron levels in the lung 
There are limited reports regarding how lung iron homeostasis is affected by imbalanced 
systemic iron levels. Here, we report that a disruption in the hepcidin/FPN regulatory circuitry 
and the subsequent increase in systemic iron levels cause pulmonary iron accumulation in a 
mouse model of HH type 4 (Slc40a1C326S). The observed increase in lung iron levels is not a 
result of the point mutation in FPN per se, since hepcidin knock out mice showed similar levels 
of pulmonary iron accumulation when compared to Slc40a1C326S/C326S mice. Increased systemic 
and pulmonary iron levels in Slc40a1C326S mice result from an increase in dietary iron uptake 
caused by the resistance of FPN to hepcidin binding. 
To date, no data is available regarding the pulmonary iron content of patients with HH type 4. 
However, the idea that increased pulmonary iron levels in humans can be caused by increased 
dietary iron uptake is supported by the report of a patient that presented signs of intracellular 
and extracellular lung iron accumulation after receiving therapeutic oral iron supplementation 
[239]. Moreover, patients with thalassemia major, a disease characterized by transfusional iron 
overload, were reported to accumulate iron in alveolar macrophages, further supporting the idea 
that increased systemic iron levels in humans can affect pulmonary iron content [240, 241].  
The IRE/IRP system is inactivated by increased intracellular iron levels (see introduction, section 
1.4). This causes the degradation of the IRE-containing transcripts encoding for DMT1 and TfR1 
and allows the translation of FtL and FPN. Consistent with the increase in pulmonary iron 
content in Slc40a1C326S mice, we observed a decrease in mRNA and protein levels of TfR1 and 
mRNA levels of the IRE-containing transcript of Dmt1, as well as an increase in the protein 
levels of FtL. These results show that the expected molecular signature is preserved in the lung 
of Slc40a1C326S mice. Furthermore, FPN protein levels showed a genotype-specific increase, 
which may result from a combined effect of increased expression at transcriptional level (Fig. 
2.2D), derepression of FPN translation by the inhibition of the IRE/IRP system [30] and the 
hepcidin-resistant phenotype that post-translationally stabilizes the protein [102]. 
Giorgi et al. reported that intraperitoneal injection of iron-saccharate in mice leads to increased 
systemic and pulmonary iron levels [208], supporting our finding that altered systemic iron 
homeostasis affects lung iron content. However, in their study the expression of TfR1 and DMT1 
in the lung did not change in response to increased pulmonary iron content [208]. The 
differences in our observations might be explained by different sources of iron (dietary iron 
versus iron-saccharate) and/or may reflect the fact that lung cells in Slc40a1C326S mice are 
chronically exposed to high levels of iron in contrast to the acute iron treatment in iron-
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saccharate injected mice. Regarding FPN expression, they observed an increase in lung FPN 
protein levels, consistent with our findings in Slc40a1C326S mice [208]. In their work, Giorgi and 
colleagues further observed an increase in ZIP14 protein levels. Unfortunately, we were unable 
to detect ZIP14 protein by western blot or immunohistochemistry in the lung of wild-type and 
Slc40a1C326S mice. 
The hormone hepcidin is mainly produced and secreted by hepatocytes and plays a major role 
in systemic iron regulation (reviewed in [28]). Hepcidin expression in cells other than 
hepatocytes has been reported, but at a much lower level [51-54]. We observed that in the lung, 
hepcidin mRNA levels are very low compared to those in the liver. Furthermore, we observed 
that contrary to hepatic hepcidin, pulmonary hepcidin expression does not respond to increased 
iron levels, as no differences were observed between wild-type and Slc40a1C326S/C326S mice. 
Giorgi and colleagues have also analyzed the expression of hepcidin in the lung of mice injected 
intraperitoneally with iron-saccharate. Consistent with our data, they observed that pulmonary 
hepcidin expression does not respond to an increased lung iron content [208]. 
Liver-specific hepcidin knock out mice completely recapitulate the hemochromatosis phenotype 
observed in the global knock out mice, highlighting the predominant role of hepatic hepcidin in 
the regulation of body iron homeostasis [242]. The role of extra-hepatic hepcidin in maintaining 
cellular or/and systemic iron homeostasis is not completely known yet. A recently published 
study has revealed a role for cardiac hepcidin in cardiac iron homeostasis through the analysis 
of mice with a cardiomyocyte-specific deletion of hepcidin [243]. Airway epithelial cells in the 
lung were shown to express hepcidin but its role in lung iron homeostasis is not clear yet [216, 
217]. Frazier and colleagues reported that an increase in hepcidin expression in human airway 
epithelial cells in vitro does not cause a decrease in FPN protein levels in these cells [216]. In 
contrast, Chen and colleagues observed that, in a mouse model of sepsis-induced acute lung 
injury, there is an increase in lung FPN protein levels upon the knock down of hepcidin in airway 
epithelial cells [217]. The generation of mice with lung cell-type specific deletion of hepcidin 
would help to better understand a possible role of lung hepcidin in the context of pulmonary iron 
homeostasis. 
The risk for oxidative stress in the respiratory tract is exceptionally high since it is continuously 
exposed to the atmosphere and consequently to high levels of oxygen and pollutants. Under 
healthy conditions, oxidative stress is prevented by the presence of antioxidants in the 
respiratory lining fluid and the presence of alveolar macrophages, which are capable of 
sequestering large amounts of iron intracellularly [203, 212]. Endogenous or exogenous 
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conditions that cause an increase in the availability of free iron in the lung can result in oxidative 
stress. For example, the pulmonary inhalation of iron oxide nanoparticles in rats leads to an 
increase of ROS in the lung [223]. We observed an increase in oxidative stress in the lung of 
Slc40a1C326S/C326S mice, which correlates with increased pulmonary iron content and the 
presence of extracellular iron in the BAL fluid, probably reflecting a saturated ability of AMs and 
other lung cells to store iron in a chemically inert form. 
 
Iron accumulation in the lung of Slc40a1C326S mice is restricted to specific 
cell types 
We observed that iron does not accumulate uniformly in the lung of Slc40a1C326S mice but in 
specific cells types: ciliated epithelial cells lining the conducting airways, alveolar type 2 cells, 
vascular smooth muscle cells and AMs. Giorgi et al. reported that in the lung of mice injected 
intraperitoneally with iron-saccharate, iron accumulates mainly in AMs [208]. Our observation 
that iron accumulates in cell types other than AMs might be explained by an acute versus 
chronic iron overload and/or differences in iron fluxes in wild-type mice intraperitoneally-injected 
with iron compared to a genetic model with a disrupted hepcidin/FPN regulatory circuitry. 
Previous work suggested that airway epithelial cells take up free catalytically active iron from the 
airway lumen [204]. We observed that in wild-type mice DMT1 is mainly expressed at the apical 
membrane of ciliated airway epithelial cells. Consistently, we frequently detected iron loaded 
ciliated cells in the conducting airways of Slc40a1C326S/C326S mice. These observations support 
the idea that these cells might be able to take up NTBI from the airway lumen. 
However, contrary to what was suggested by Ghio and colleagues [211], we believe that ciliated 
airway epithelial cells do not export iron through FPN since we detected iron deposition in these 
cells in Slc40a1C326S/C326S mice – the resistance of FPN to hepcidin binding should otherwise 
cause uncontrolled iron export. Interestingly, Giorgi and colleagues have detected FPN in the 
cytoplasm and not in the plasma membrane of airway epithelial cells, a finding that would argue 
against an active iron export via FPN [208]. 
Occasionally, we detected iron in another epithelial cell type of the lung of Slc40a1C326S mice – 
alveolar type 2 cells. How iron is imported into these cells still remains to be elucidated. 
Finally, we observed iron accumulation in vascular SMCs of the lung of Slc40a1C326S/C326S mice. 
Notably, we could also detect iron-spared vascular SMCs in Slc40a1C326S/C326S mice indicating 
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that vascular SMCs are heterogeneous in regard to iron loading. Phenotypic diversity has been 
described in vascular SMCs and correlates with different functions, ranging from a contractile to 
a synthetic function [244]. The expression levels of different SMC markers are commonly used 
to define different phenotypes; for example, higher levels of desmin expression were associated 
with a contractile phenotype [244]. In Slc40a1C326S/C326S mice, iron accumulates in vascular 
SMCs that appear to be functionally different: iron-spared vascular SMCs express high levels of 
desmin whereas iron-loaded vascular SMCs show lower levels of desmin. Since vascular SMCs 
have a critical role in the normal regulation of the blood flow and pressure, we have an ongoing 
project in the laboratory to address how increased systemic iron levels and/or iron accumulation 
in a sub-population of vascular SMCs in Slc40a1C326S/C326S mice affects their role in maintaining 
appropriate blood pressure under physiological and/or pathophysiological conditions. It is worth 
to mention that altered iron homeostasis was reported in patients with idiopathic pulmonary 
arterial hypertension [245]. Iron deficiency in rats was shown to cause pulmonary vascular 
remodeling and was associated with increased pulmonary arterial hypertension, which can be 
reverted by iron treatment [246]. 
 
Iron loaded alveolar macrophages and inflammatory status of Slc40a1C326S 
mice 
Iron sequestration by AMs has been described in different lung diseases and has been 
recognized as a powerful protective mechanism against cytotoxic iron catalyzed oxidants [204, 
212, 218]. We analyzed AMs from Slc40a1C326S/C326S mice and showed that their number is 
increased when compared to wild-type animals. Whether this increase is due to a recruitment of 
circulating monocytes or results from the proliferation of a progenitor population within the lung is 
still not known. Even though monocyte recruitment has been mainly connected with increased 
tissues levels of CCL2, we did not detect an increase in mRNA levels of Ccl2 in the lung of 
Slc40a1C326S/C326S mice. Nevertheless, we observed a strong tendency for an increase in the 
levels of CCL2 in the plasma of Slc40a1C326S/C326S mice, which may contribute for the recruitment 
of monocytes into tissues. It is worth to mention that Slc40a1C326S/C326S mice also show an 
increase in the number of peritoneal macrophages (unpublished data from our laboratory), which 
might also be a consequence of increased systemic levels of CCL2. To further understand if 
there is a recruitment of circulating monocytes to the lung of Slc40a1C326S/C326S mice, it would be 
interesting to perform fate-mapping studies to trace monocyte progeny in Slc40a1C326S/C326S mice 
[182]. We have also detected a mild increase in the levels of Cxcl1 in the lung of 
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Slc40a1C326S/C326S mice, which is commonly associated with neutrophil recruitment. However, the 
increase in the number of neutrophils in the bronchoalveolar space was not statistically 
significant (Fig. 2.12B). 
We detected strong iron deposition in AMs from Slc40a1C326S/C326S mice. This was an 
unexpected result since, in the same mouse model, other resident macrophages such as 
Kupffer cells and splenic macrophages are iron depleted due to the presence of a hepcidin-
resistant FPN on the cell surface of these cells [102]. Interestingly, we also observed iron spared 
AMs, indicating that the population of AMs in Slc40a1C326S/C326S mice is heterogeneous in regard 
to iron handling. This heterogeneity in iron accumulation most likely results from a 
heterogeneous expression of FPN in AMs isolated from Slc40a1C326S/C326S mice. Notably, we 
could not detect AMs expressing FPN in wild-type mice. This result contrasts with a previous 
study, in which FPN was detected in intracellular vesicles of murine AMs [210]. 
How FPN expression is regulated in AMs is still not known. GM-CSF, which is known for its key 
role in AM differentiation and which is highly expressed in the lung, has been described to 
repress FPN expression in monocyte-derived macrophages upon stressed erythrocyte challenge 
[234]. In line with this idea, we demonstrated the ability of GM-CSF to downregulate FPN 
expression in BMDM in vitro. Nevertheless, we observed AMs expressing FPN in 
Slc40a1C326S/C326S mice. The presence of GM-CSF in the lung would be expected to suppress 
FPN expression. We speculate that FPN-positive AMs correspond to recruited macrophages 
that do not respond to the presence of GM-CSF in the lung or to macrophages still undergoing 
the differentiation process. 
Our laboratory has previously described that iron overload in reticuloendothelial macrophages 
results in oxidative stress and triggers a pro-inflammatory status [238]. Since we detected 
increased iron levels in AMs, we analyzed the degree of oxidative stress in these cells and the 
pulmonary inflammatory status of Slc40a1C326S/C326S mice. We did not detect differences in 
oxidative stress between AMs of wild-type and Slc40a1C326S/C326S mice. By contrast, BMDM show 
a strong increase in oxidative stress after an acute iron treatment. The absence of oxidative 
stress in AMs probably results from an adaptation of these cells to chronic iron accumulation. 
Consistent with the absence of oxidative stress, AMs from Slc40a1C326S/C326S mice do not appear 
to be morphologically activated since we did not detect an increase in cell size when compared 
to wild-type AMs.  
Lung inflammation is hallmarked by an increased expression of pro-inflammatory cytokines and 
a strong recruitment of immune cells into the bronchoalveolar compartment [247]. Despite the 
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increase in the number of AMs, but in agreement with the lack of oxidative stress in these cells, 
we did not observe a strong and robust increase in the expression of inflammatory cytokines in 
the lung of Slc40a1C326S/C326S mice (Fig. 2.13; Fig. 2.17). Interestingly, the inhalation of iron-rich 
particles leads to increased oxidative stress and lung inflammation [222-224]. This difference in 
terms of pulmonary inflammation in response to increased iron levels is probably a consequence 
of the different sources of iron (dietary iron versus inhalation of iron-rich particles) and a 
difference in the exposure to iron (chronic versus acute). Despite the absence of pulmonary 
inflammation in Slc40a1C326S/C326S mice, increased iron levels in the lung, and in particular in the 
AMs, might affect the inflammatory response to pathogens. For example, low intracellular iron in 
macrophages impairs signaling via the TLR4 pathway leading to reduced production of LPS-
induced cytokines [248]. An interesting follow up would be to perform LPS instillation in 
Slc40a1C326S/C326S mice and analyze the production of inflammatory cytokines and the recruitment 
of neutrophils to the bronchoalveolar space. Previous work from our group has described the 
acute pulmonary inflammatory response of Hfe knock out mice upon intratracheal instillation of 
LPS [247]. The study showed that the production of inflammatory cytokines was affected and 
that there was an impairment in the recruitment of neutrophils to the lung of Hfe knock out mice. 
However, in this study it was not possible to understand whether the observed effects were due 
to the increase in systemic iron levels or due to the absence of HFE itself. Furthermore, Hfe 
knock out mice do not present increased pulmonary iron content when compared to wild-type 
mice [247]. 
In healthy lungs, the availability of free iron must be limited not only to reduce the risk of 
oxidative stress but also to prevent pulmonary infections [249]. For example, increased iron 
levels in the airways were related to the persistence of Pseudomonas aeruginosa infection in 
cystic fibrosis patients [250]. Moreover, during Pseudomonas aeruginosa infection, the murine 
host up-regulates the expression of proteins involved in iron-sequestration, highlighting the 
concept that the competition for iron between the host and the pathogens is crucial to determine 
the outcome of an infection [251]. Due to the increase in pulmonary iron content in 
Slc40a1C326S/C326S mice, and particularly the presence of extracellular iron in the bronchoalveolar 
space, it would be interesting to infect these animals with Pseudomonas aeruginosa and 
determine whether they are more susceptible to infection. 
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Slc40a1C326S/C326S mice show classical signs of restrictive lung disease and 
decreased blood oxygen saturation 
An increase in oxidative stress, resulting from increased iron levels, is known to cause cellular 
damage and tissue injury [2, 102, 233]. Increased pulmonary iron levels in Slc40a1C326S/C326S 
correlate with an increase in lipid peroxidation, suggesting that iron-mediated oxidative stress 
could contribute to the pathogenesis of lung diseases. To determine whether increased iron 
content affects pulmonary function, we performed measurements of lung function on aged mice. 
This analysis revealed that Slc40a1C326S/C326S mice present classical signs of restrictive lung 
disease, such as decreased total lung capacity, decreased pulmonary compliance and 
increased elastance. Furthermore, stereological analysis of the lung revealed that the decrease 
in total lung capacity in Slc40a1C326S/C326S mice results from a reduction in the volume of the lung 
parenchyma. 
To date, there are no reports of impaired lung function in human patients with HH type 4. 
However, this may reflect the fact that patients identified with the FPN C326S mutation were 
heterozygous [100] and clinical iron overload has been controlled by phlebotomy. 
Interestingly, restrictive lung disease is the major pulmonary dysfunction observed in patients 
with thalassemia major [252-257]. These patients are hallmarked by increased systemic iron 
levels and parenchymal iron overload. Furthermore, iron accumulation has been observed in 
AMs isolated from the BAL [240, 241]. Some studies reported that the restrictive pattern 
correlates with serum ferritin levels and/or with age (which may reflect a chronic effect of iron 
overload) [254, 256]. Our results strengthen the idea that the pulmonary restrictive pattern in 
thalassemia patients may be a consequence of chronic iron overload. 
A restrictive pattern is commonly associated with pulmonary fibrosis. However, histological 
analysis of the lung of Slc40a1C326S/C326S mice did not reveal significant alterations in lung 
collagen deposition. Even though the mechanism(s) leading to restrictive lung disease in 
Slc40a1C326S/C326S mice is still not known, we can speculate about two possible causes: 
pulmonary edema or altered function of the surfactant. 
Increased iron levels and iron-mediated oxidative stress have been reported to disrupt the 
blood-brain barrier permeability [258]. Consistently, unpublished data from our laboratory also 
indicate that blood vessel permeability is affected by increased iron levels and/or oxidative 
stress. We hypothesize that vessel permeability in the lung of Slc40a1C326S/C326S mice might be 
compromised due to increased systemic and pulmonary iron levels and the subsequent increase 
in oxidative stress. This would lead to fluid accumulation within the lung and contribute to the 
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decrease in total lung capacity measured by pulmonary function tests. In addition, the increase 
in blood vessel permeability in the lung would also offer a plausible explanation for the increase 
in iron levels in the bronchoalveolar space. We have tried to test this hypothesis by injecting 
Evans blue dye into the tail vein of Slc40a1C326S/C326S mice. Due to its high affinity to serum 
albumin, this dye should not accumulate in the tissues when vessel permeability is intact. 
Unfortunately, for reasons that are still not clear, vessels in the Slc40a1C326S/C326S mice are very 
fragile, making tail vein injection hard to perform in a consistent and reproducible way. 
The pulmonary surfactant decreases surface tension at the gaseous-aqueous interphase of the 
lung, preventing it from collapsing and facilitating inflation [158]. We can speculate that the 
oxidation of surfactant proteins and lipids by the presence of extracellular iron in the 
bronchoalveolar space of Slc40a1C326S/C326S mice might alter the structure and function of the 
surfactant, increasing the surface tension and making it harder to inflate. This would explain the 
decrease in pulmonary compliance and increase in elastance observed in Slc40a1C326S/C326S 
mice. Supporting this hypothesis, Rodriguez-Capote and colleagues showed that surfactant 
oxidation caused by ROS interferes with its function through the oxidation of surfactant 
phospholipids and proteins [259]. 
The main function of the lung is to allow for an efficient gas exchange between the atmosphere 
and the bloodstream, in order to fulfill the oxygen requirements of all cells of the organism and to 
excrete the waste CO2 produced during cellular respiration. Since lung function is impaired in 
Slc40a1C326S/C326S mice, we analyzed blood oxygen saturation. We observed a strong decrease 
in oxygen saturation in Slc40a1C326S/C326S compared to wild-type mice. The restrictive pattern 
observed in Slc40a1C326S/C326S mice probably contributes to the observed hypoxemia but most 
likely cannot fully explain such a strong phenotype. We can hypothesize that the reduction in 
blood oxygen saturation can be caused by 1) a substantial ventilation/perfusion mismatch, 2) a 
shunt flow of the blood, or 3) by a low cardiac output. Regarding the first hypothesis, it is 
possible that an impairment of surfactant production and/or activity might lead to a partial 
collapse of gas exchanging units within the lung resulting in ventilation/perfusion mismatch and 
hypoxemia. Second, alterations in the vasculature may cause a shunting of unoxygenated blood 
across the heart or the lungs. Finally, low cardiac output could also contribute to such a 
phenotype by causing low venous oxygenation and leading to low arterial O2 saturation. Future 
studies will be necessary to address these possibilities. 
In adult mammals, systemic hypoxia is mainly sensed by the kidney, in particular by peritubular 
fibroblasts of the renal cortex [81]. These cells produce and secrete EPO in response to 
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hypoxia: low oxygen levels lead to the stabilization of the transcription factor subunit HIF-2α 
which, together with HIF-β, activates Epo transcription [86]. Consistently, we detected increased 
levels of EPO in the plasma of Slc40a1C326S/C326S mice. Erythropoiesis in the bone marrow is 
stimulated by increased levels of circulating EPO, in an attempt to restore the proper delivery of 
oxygen to cells. In agreement with these findings, high levels of red blood cells, hemoglobin and 
hematocrit were detected in Slc40a1C326S/C326S mice. It is worth to mention that elevated 
intracellular iron levels in Slc40a1C326S/C326S mice can also directly activate EPO production via 
the IRP/IRE system – IRP1 is converted from its RNA-binding form to the cytoplasmatic 
aconitase form containing a [4Fe–4S] cluster and consequently cannot bind the IRE present in 
the 5’ UTR of the HIF-2α mRNA, leading to an increase in its translation [260]. 
Hepatic hepcidin transcriptional expression is regulated by different stimuli (see introduction, 
section 1.5.2). Interestingly, Slc40a1C326S/C326S mice show increased systemic iron levels but 
decreased blood oxygen saturation. These two stimuli are expected to have opposite effects on 
hepcidin transcription: high levels of iron stimulate hepcidin expression whereas hypoxia 
represses hepcidin expression. As previously reported by us, liver hepcidin expression is 
increased in Slc40a1C326S/C326S mice [102], indicating that increased iron levels are dominant over 
hypoxic signals in controlling hepcidin expression. Nevertheless, since hypoxia represses 
hepcidin expression indirectly by inducing erythropoiesis and therefore increasing ERFE, it 
would be interesting to analyze ERFE levels in the plasma of Slc40a1C326S/C326S mice. 
Additionally, hypoxia can also indirectly repress hepcidin expression by the upregulation of 
TMPRSS6 and furin expression caused by HIF-1α stabilization [66, 89]. 
 
Slc40a1C326S/C326S mice present increased plasma iron levels, hepatic iron overload, body weight 
loss, and exocrine pancreatic failure [102]. For this reason, we cannot exclude that 
pathophysiological consequences of iron overload in Slc40a1C326S/C326S mice other than the lung 
may contribute to our observations. The restrictive pattern and decreased blood oxygen 
saturation may result from a combination of high iron levels in the lung and other impairments 
caused by increased systemic iron levels and tissue iron deposition. Finally, we can speculate 
that an impaired lung function may contribute to the premature death observed in 
Slc40a1C326S/C326S mice [102]. 
 
As a conclusion, our findings implicate iron overload in lung pathology, which is so far not 
considered a classical iron-related disorder. With the exception of some studies in thalassemia 
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patients, there is limited information regarding the pulmonary consequences of systemic and 
lung iron overload in humans. Future analysis of lung iron content and lung function in patients 
with iron-related diseases such as hereditary hemochromatosis will be essential to further 
understand the physiological consequences of iron overload in human lung disorders. 
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Imbalances of iron homeostasis are implicated in a spectrum of
acute and chronic lung diseases (Ghio, 2009; Ghio et al., 2013). In
patients with chronic obstructive pulmonary disease (COPD), iron de-
posits in alveolar macrophages (AM) and the percentage of iron loaded
macrophages is associated with increased disease severity (Philippot et
al., 2014). On the other hand thalassemiamajor, a disease characterized
by transfusional iron overload, has been associated with impaired lung
function (Carnelli et al., 2003; Guidotti et al., 2016; Kanj et al., 2000).
However, whether pulmonary iron accumulation contributes to disease
onset and progression is poorly understood.
Tissue iron levels must be maintained in such a way that both iron
deﬁciency and iron overload are prevented. Excess free iron generates
oxidative stress causing cell damage and tissue injury (Muckenthalerelberg.de (M.U. Muckenthaler).
. This is an open access article underet al., 2017). In the lung, the risk for oxidative stress is exacerbated by
its continuous exposure to an atmosphere with high oxygen levels.
The mechanisms maintaining lung iron homeostasis are incompletely
understood. Like most other cells, lung cells acquire transferrin-bound
iron from the plasma. In addition, lung airway epithelial cells take up
iron via the divalent metal transporter 1 (DMT1) and sequester it in
the iron storage protein ferritin (Ghio, 2009; Wang et al., 2002). Upon
iron exposure, pulmonary ferritin levels increase, possibly protecting
from oxidative stress (Ghio, 2009; Ghio et al., 1998; Giorgi et al., 2015).
The supply of iron to the lung depends on its systemic plasma
availability, which is controlled by the hepcidin/ferroportin regula-
tory axis (Muckenthaler et al., 2017). Hepatic hepcidin produced in
response to increased systemic iron levels binds to the iron exporter
ferroportin (FPN) to control its internalization, ubiquitination and
subsequent lysosomal degradation (Nemeth et al., 2004; Qiao et al.,
2012). In turn, this decreases iron efﬂux from exporting cells, such as
duodenal enterocytes and reticuloendothelial macrophages. Mutations
in the iron exporter FPN that confer resistance to hepcidin binding
cause hereditary hemochromatosis (HH) type 4, a genetically inheritedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
231J. Neves et al. / EBioMedicine 20 (2017) 230–239primary iron overload disorder hallmarked by increased systemic iron
levels, iron depletion in iron-exporting organs and severe iron deposi-
tion in parenchymal tissues (Altamura et al., 2014; Sham et al., 2009;
Sham et al., 2005).
Here, we aim to understand whether a disruption in the FPN/
hepcidin regulatory system and the subsequent increase in systemic
iron levels affect lung iron homeostasis and function. To achieve this
goal, we took advantage of a murine disease model of HH type 4,
hallmarked by a C326S amino acid substitution in FPN (Slc40a1C326S)
(Altamura et al., 2014). We show that resistance of ferroportin to
hepcidin binding causes pulmonary iron accumulation in deﬁned
lung cell types. Homozygous Slc40a1C326S/C326S mice show increased
oxidative stress in the lung, restrictive lung disease and decreased
blood oxygen saturation, revealing a role of iron in lung pathology.
2. Material and Methods
2.1. Mice
All mice analyzed were maintained on a pure C57BL/6N genetic
background (N99.9% congenic). As controls, age- and gender-matched
wild-type C57BL/6Nmice born andmaintained in the same breeding fa-
cility were used. Mice were housed in the Heidelberg University animal
facility under a constant light-dark cycle and maintained on a standard
mouse diet (LASQCdiet Rod18-A - LASvendi) containing 200 ppm iron
with ad libitum access to food and water. All mouse breeding and ani-
mal experiments were approved by the RegierungspräsidiumKarlsruhe
(Projects Nr T-81/14, T-66/13, G-41/16, G-39/16).
2.2. Tissue Iron Quantiﬁcation
Tissue non-heme iron content was measured using the
bathophenanthroline method and calculated against dry weight tissue
(Torrance and Bothwell, 1968).
2.3. RNA Extraction, Reverse Transcription and qRT-PCR
Total lung RNAwas isolated using Trizol (Life technologies) andwas
reverse transcribed and used in SYBR-green qPCR, as described in
(Altamura et al., 2010). mRNA expression was calculated relative to
RPL19 and data were analyzed using the ΔΔCt method (Livak and
Schmittgen, 2001). The primers used are listed in Supplementary
Information.
2.4. Western Blotting
Protein lysates were obtained by homogenizing snap-frozen tissues
in RIPA buffer supplemented with protease inhibitors (Roche Diagnos-
tics), as described in (Galy et al., 2004). Protein concentration was de-
termined using the DC protein assay (BioRad). 50 μg of protein were
subjected to western-blot analysis with the antibodies listed in Supple-
mentary Information. Western blot images were quantitatively ac-
quired with the Vilber Lourmat Fusion-FX Chemiluminescence system
(Eberhardzell). β-actin was used as loading control.
2.5. Lipid Peroxidation - TBARS Measurements
Thiobarbituric acid reactive substances (TBARS) levels were
measured in samples of total lung from 36-week old mice using the
QuantiChrom TBARS Assay Kit (BioAssay Systems) following
manufacturer's instructions.
2.6. Bronchoalveolar Lavage and Differential Cell Count
Mice were anesthetized via intraperitoneal injection of a combina-
tion of ketamine and xylazine (120 and 16 mg/kg respectively) andsacriﬁced by exsanguination. A median sternotomy was performed,
the trachea cannulated and the left mainstem bronchus ligated, and
the right lung was lavaged with Phosphate Buffered Saline (PBS). Bron-
choalveolar lavage (BAL) sampleswere centrifuged and BAL ﬂuid super-
natant was harvested and stored at −80 °C. Total cell counts were
determined using a haemocytometer and differential cell counts were
determined in cytospin preparations stained with May–Grünwald–
Giemsa (Merck).
2.7. Iron Quantiﬁcation in the Bronchoalveolar Lavage Fluid Supernatant
BAL ﬂuid supernatant was concentrated through Speed-Vacuum.
Iron measurements were performed using the SFBC kit (Biolabor) fol-
lowing manufacturer's instructions.
2.8. Measurement of Cytokine Protein Levels in Bronchoalveolar Lavage
Cytokine protein levels (IL6, IL1β and TNFα) were determined in
BAL ﬂuid supernatants applying Multiplex bead-array based technolo-
gy. Measurements were performed on a BioPlex200 System using the
Bio-Plex Pro Cytokine Reagent Kit and Bio-Plex Pro Mouse Cytokine
sets (Bio-Rad) according to manufacturer's instructions. Cytokine pro-
tein levels are given as picograms in total BAL ﬂuid supernatant.
2.9. Lung Function Measurements
Mice were anesthetized via intraperitoneal injection of Na+-pen-
tobarbital (80 mg/kg), tracheostomized and placed on the FlexiVent
system (SCIREQ, Montreal, QC, Canada) for measurements of pulmo-
nary function. Mice were then paralyzed with pancuronium bromide
injected intraperitoneally (0.8 mg/kg) to avoid breathing artefacts
during the measurement. Mice were ventilated at a frequency of
150 breaths/min, with a tidal volume of 11 mL/kg and a positive
end expiratory pressure of 3 cm H2O to prevent alveolar collapse.
Pressure-volume curves, total lung capacity, pulmonary compliance
and elastance were measured as previously described in (Mall et al.,
2008) and (Vanoirbeek et al., 2010). All perturbations were performed
until at least three acceptable measurements were reached.
2.10. Blood Oxygen Saturation
Oxygen saturation was determined using a noninvasive pulse oxim-
eter for laboratory animals (MouseOx® Plus, Starr life science) follow-
ing manufacturer's instructions. Arterial blood oxygen saturation was
analyzed in consciousmice exposed to room air with a thigh clip sensor.
The oxygen saturation was measured when pulse waves were stable
and regular in order to obtain valid values.
2.11. Stereology of Lung Tissue
Lungs from 36 week old mice were instilled via the trachea with
1.5% paraformaldehyde, 1.5% glutaraldehyde in 0.15 M Hepes buffer
at hydrostatic pressure of 25 cm and stored in the same solution at 4
°C until further processing. The lungs were embedded in glycol
methacrylate according to standard protocol (Muhlfeld et al., 2013)
and 1.5 μm thick sections were cut. Light microscopy was performed
using a Leica DM6000B microscope (Leica, Wetzlar, Germany)
attached to a computer with the newCAST stereology software
(Visiopharm, Horsholm, Denmark). Design-based stereology was
used to quantify the volume of the lung parenchyma and non-paren-
chyma as described in (Muhlfeld et al., 2013).
2.12. Erythropoietin (Epo) Measurements
Plasma Epo levels were determined using a mouse Epo ELISA kit
(R&D systems) following manufacturer's instructions.
232 J. Neves et al. / EBioMedicine 20 (2017) 230–2392.13. Isolation and Differentiation of Bone Marrow Derived Macrophages
(BMDM)
Bone marrow cells were ﬂushed from tibia and femur using ice-
cold Hank's balanced salt solution (HBSS) and ﬁltered through a 70
μm cell strainer (BD biosciences). Cells were seeded at a density of
350,000 cells/cm2 in RPMI1640-Glutamax medium (Life Technologies)
supplemented with 10% of heat-inactivated fetal bovine serum
(Hyclone, Thermo scientiﬁc), 1% Penicillin/streptomycin (Gibco) and
10 ng/mLM-CSF (Peprotech). After 4 days, non-adherent cells were re-
moved by HBSS washing and the medium was replaced daily until cell
harvesting (6 days after seeding). Before harvesting, BMDMwere treat-
ed overnight with 75 μM of iron-nitrilotriacetate (FeNTA).
2.14. Immunohistochemistry and Immunocytochemistry
Lungs were inﬂated with 4% neutral buffered formalin (Fischar) to
25 cmofﬁxative pressure,ﬁxed overnight by immersion in the same so-
lution, dehydrated and parafﬁn embedded. Lungs were sectioned at 1.5
or 5 μm and mounted on Superfrost Plus slides (ThermoFisher scientif-
ic). Lung sections were rehydrated and treated for 10minwith 3%H2O2
(Sigma Aldrich) to block endogenous peroxidases. After washing in
distilled water, tissue slides were subjected to microwave-mediated
antigen retrieval using the Citraplus reagent (Biogenex). After
30 min of cooling, slides were washed 3 times in PBS and subjected
to immunorecognition using Vectastain ABC mouse and rabbit kits
(Vector Lab, Burlingame, CA, USA) following manufacturer's instruc-
tions. BAL cells in cytopsin preparations were ﬁxed in cold acetone
(−20 °C) for 10 min, washed in PBS and treated for 10 min with 3%
H2O2 (Sigma Aldrich) to block endogenous peroxidases. After wash-
ing in PBS, cytospin slides were subjected to immunorecognition
using the Vectastain ABC rabbit kit (Vector Lab, Burlingame, CA,
USA) following manufacturer's instructions. Antibody dilutions and
catalog numbers are reported in Supplementary information. Isotype
antibodies were used at the same concentration as the primary anti-
bodies to control for antibody speciﬁcity. Slides were developed
using the Vector AEC substrate (Vector lab), rinsed with distilled
water, counterstained with Hematoxylin, washed in PBS and
mounted using the VectaMount AQ mounting medium (Vector lab).
Images were digitally acquired with a Nikon Ni-E microscope
(Nikon Center of the University of Heidelberg), using the Nikon
NIS-Elements software. Splenic cells in cytospin preparations were
subjected to the same protocol as BAL cells in cytospin preparations
and used as a positive control for FPN immunocytochemistry.
2.15. DAB-enhanced Perls' Stain
Lungs were inﬂated with 4% neutral buffered formalin (Fischar)
to 25 cm of ﬁxative pressure, ﬁxed overnight by immersion in the
same solution, dehydrated and parafﬁn embedded. Lungs were sec-
tioned at 1.5 or 5 μm and mounted on Superfrost Plus slides
(ThermoFisher scientiﬁc). Lung sections were rehydrated and
stained for 10 min with a potassium ferrocyanide/HCl solution
(Sigma Aldrich). After washing in distilled water, slides were treated
with 3,3-diaminobenzidinetetrahydrochloride (DAB) (Sigma Al-
drich). Slides were washed again in distilled water, counterstained
with Hematoxylin, washed in PBS, dehydrated and mounted using
the Eukitt quick-hardening mounting medium (Sigma Aldrich).
2.16. Perls' Stain
BAL cells in cytopsin preparations were stained with potassium fer-
rocyanide/HCl solution (Sigma Aldrich), washed in distilled water and
counterstained with Fast Red (Sigma Aldrich). Images were digitally ac-
quired with a Nikon Ni-E microscope, using the Nikon NIS-Elements
Viewer software.2.17. Hematoxylin and Eosin Stain
Parafﬁn lung sections were rehydrated and stained for 6 min with
Mayer's Hematoxylin (Sigma Aldrich). Slides were washed in water,
rinsed in HCl/EtOH, washed again in water and stained for 1 min with
Eosin Y (Sigma Aldrich). Slides were dehydrated and mounted using
the Entellan new mounting medium (Merck).
2.18. Masson Goldner Trichrome Stain
Parafﬁn lung sections were rehydrated and stained with Masson
Goldner Trichrome Staining Kit (Carl Roth) following manufacturer's
instructions.
2.19. Analysis of Lung Collagen Content
Parafﬁn lung sections (3 μm)were stainedwith 0.1% Sirius red so-
lution as previously described (Kosanovic et al., 2011). The degree of
ﬁbrosis was calculated by the analysis of the total amount of collagen
in the left lung (Leica Microsystem, Wetzlar, Germany). For evalua-
tion of the percentage of collagen, the collagen positive areas (red ﬁ-
bers) were determined in a minimum of 300 images per animal.
2.20. Flow Cytometry Analysis
Cells obtained from BAL were stained with CD45.2, CD11c and
SiglecF antibodies for 30 min on ice (antibody dilutions and catalog
numbers are reported in Supplementary information). To measure oxi-
dative stress, BAL cells and BMDMwere incubated for 30min at RTwith
5 μM CellROX Green reagent (ThermoFisher). After washing, cells were
analyzed by ﬂow cytometry using the BD LSRFortessa Cell Analyzer.
2.21. Statistical Analyses
Data are shown asmean± SEM. Statistical analyseswere performed
using Prism v6 (GraphPad Software, La Jolla, CA). Two-tailed, Student's
t-test was used and p-values b 0.05 (*), b0.01 (**), b0.001 (***) and
b0.0001 (****) are indicated.
3. Results
3.1. Iron Levels are Increased in the Lung of Slc40a1C326S Mice
Slc40a1C326Smice, a diseasemodel of HH type 4, is hallmarked by in-
creased systemic iron levels, iron deposition in parenchymal tissues and
iron depletion in iron exporting organs (Altamura et al., 2014). We now
analyzed lung tissue of male and female heterozygous Slc40a1wt/C326S
and homozygous Slc40a1C326S/C326S mice and demonstrate that iron ac-
cumulates in an age- and genotype-dependent manner (Fig. 1A).
Under physiological conditions, elevated cellular iron levels inacti-
vate the iron-responsive element/iron-regulatory protein (IRE/IRP) sys-
tem. This causes degradation of the transcripts encoding for the iron
importers divalentmetal transporter 1 (DMT1) and transferrin receptor
1 (TfR1) and allows for the translation of the iron storage protein ferritin
light chain (FtL) and ferritin heavy chain (FtH) as well as for the iron ex-
porter FPN (Anderson et al., 2012; Muckenthaler et al., 2008). Accord-
ingly, mRNA and protein expression of TfR1 and mRNA expression of
the IRE-containing transcript of DMT1 are decreased in iron loaded
lungs of Slc40a1wt/C326S and Slc40a1C326S/C326S mice (Fig. 1B, C, D),
while FtL protein expression is increased (Fig. 1D). Furthermore, FPN
expression shows a genotype-speciﬁc increase both at mRNA and pro-
tein levels (Fig. 1D, E).
Excess of iron generates reactive oxygen species (ROS) that will
damage proteins, lipids and DNA (Altamura and Muckenthaler, 2009;
Papanikolaou and Pantopoulos, 2005). Consistently, increased pulmo-
nary iron levels in Slc40a1C326S/C326S mice correlate with increased
Fig. 1. Slc40a1C326S mice show increased pulmonary iron content. A) Total lung non-heme iron levelsmeasured inmale and female 10-, 24- and 36-week oldmice. B) qRT-PCR analysis of
TfR1mRNA expression in total lung of female 36-week oldmice. C) qRT-PCR analysis of DMT1-IREmRNA expression in total lung of female 36-week oldmice. D)Western Blot analysis of
TfR1, FtL and FPN protein expression in total lung of female 36-week oldmice. β-actinwas used as loading control. E) qRT-PCR analysis of FPNmRNA expression in total lung of female 36-
week oldmice. F) qRT-PCR analysis of HO1mRNA expression in total lung of female 36-week oldmice. G) Lipid peroxidationmeasured by the TBARS assay in total lung of female 36-week
old mice.
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Fig. 2. Iron accumulation in the lung of Slc40a1C326S/C326Smice is restricted to speciﬁc cell types. A) DAB-enhanced Perls' staining of lung sections of female 36-week oldmice. Arrow shows
an alveolarmacrophagewith strong iron accumulation. B) Immunohistochemistry for DMT1 (left) andβ-tubulin IV (right) of consecutive lung sections fromwild-type female 36-weekold
mice. C) DAB-enhanced Perls' staining (left) and immunohistochemistry for β-tubulin IV (right) of consecutive lung sections from Slc40a1C326S/C326S female 26-week oldmice. D) Higher
magniﬁcation of DAB-enhanced Perls' staining (left) and immunohistochemistry for β-tubulin IV (right) of consecutive lung sections from Slc40a1C326S/C326S female 26-week oldmice. E)
DAB-enhanced Perls' staining (right) and immunohistochemistry against prosurfactant protein C (proSP-C) (left) of consecutive lung sections from Slc40a1C326S/C326S female 36-week old
mice. Arrows indicate alveolar type II cells. F)DAB-enhancedPerls' staining (left and center) and immunohistochemistry for alpha smoothmuscle actin (αSMA) (right) of consecutive lung
sections from Slc40a1C326S/C326S female 36-week old mice. G) Iron levels measured in the bronchoalveolar lavage (BAL) ﬂuid supernatant of 10-, 26- and 36-week old mice.
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235J. Neves et al. / EBioMedicine 20 (2017) 230–239heme oxygenase 1 (HO-1) mRNA expression, a marker for oxidative
stress (Fig. 1F), and with elevated lipid peroxidation (Fig. 1G).
Collectively, our results show that the disruption of the hepcidin/
FPN regulatory axis causes iron overload and oxidative stress in the
lung.
3.2. Iron Accumulates in Speciﬁc Pulmonary Cell Types in Slc40a1C326S Mice
Histological analysis of the lung of Slc40a1C326S mice conﬁrmed the
iron overload phenotype and revealed that iron deposition is restricted
to speciﬁc cell types (Fig. 2A).
Previous reports suggested that airway epithelial cells acquire iron
from the airway lumen via DMT1 (Ghio, 2009). In wild-type mice, we
detected DMT1 mainly at the apical membrane of ciliated airway epi-
thelial cells (Fig. 2B). In line with this observation, iron was commonly
detected in ciliated epithelial cells lining the conducting airways of
Slc40a1C326S/C326S mice (Fig. 2C and D). In addition, iron was detected
in a subset of another pulmonary epithelial cell type - alveolar type II
cells, which line the gas exchanging distal airspaces and produce surfac-
tant proteins such as prosurfactant protein C (Fig. 2E).
Furthermore, vascular smooth muscle cells (SMC) characterized
by expression of alpha smooth muscle actin stain for iron (Fig. 2F).
Interestingly, vascular SMCs are heterogeneous in regard to iron
loading, whereby some show iron overload while others are iron-
spared (Fig. S1A). This observation implies that the lung contains at
least two populations of vascular SMCs that are hallmarked by differ-
ential iron trafﬁcking. Future studies will have to determine whether
different populations of vascular SMCs in terms of iron handling may
reﬂect upon their role in maintaining appropriate blood pressure
under physiological and/or pathophysiological conditions.
Importantly, increased iron levels were also detected in the bron-
choalveolar lavage (BAL) ﬂuid of Slc40a1C326S mice (Fig. 2G).
3.3. Alveolar Macrophages Accumulate Iron in Slc40a1C326S/C326S Mice
Iron accumulation in alveolar macrophages (AM) is a hallmark of
certain lung diseases (Ghio et al., 2013; Philippot et al., 2014). Analysis
of histological sections of Slc40a1C326S/C326S mice revealed severe iron
accumulation in AM (Fig. 2A arrow).We next analyzed the cellular frac-
tion of the BAL by differential May-Grünwald-Giemsa stain and showed
that AM were the predominant cell type in the BAL ﬂuid of wild-type
and Slc40a1C326S/C326S mice (Fig. 3A, Fig. 3B). Interestingly, the total
number of cells in theBALﬂuid of Slc40a1C326S/C326Smicewas increased,
which is explained by an increase in AM (Fig. 3B), a ﬁnding conﬁrmed
by ﬂow cytometry (Fig. 3C) (Misharin et al., 2013). In both wild-type
and Slc40a1C326S/C326S mice, N90% of the immune cells in the BAL ﬂuid
correspond to AM (CD45.2+ CD11c+ SiglecF+) (Fig. 3D). Perls' staining
of cytospin preparations revealed severe iron overload in AM of
Slc40a1C326S/C326S mice (Fig. 3E). This iron retention phenotype distin-
guishes AM from hepatic Kupffer cells or splenic reticuloendothelial
macrophages in Slc40a1C326S/C326S mice, which are iron depleted
(Altamura et al., 2014). It is of note that in the same cell preparations
of Slc40a1C326S/C326S mice we also detected iron spared AM (Fig. 3E,
arrow), indicating that the population of AM in Slc40a1C326S/C326S mice
is heterogeneous regarding iron handling. A heterogeneity in iron accu-
mulation in AM of Slc40a1C326S/C326S mice is possibly explained by a dif-
ferential expression of FPN (Fig. 3F).
We previously showed that macrophage iron overload results in ox-
idative stress, which triggers a pro-inﬂammatory status (Vinchi et al.,
2016). We next investigated the degree of oxidative stress in AM as
well as the pulmonary inﬂammatory status in Slc40a1C326S/C326S mice.
By applying the CellROX green as ROS reporter, we failed to detect
differences in oxidative stress in AM between wild-type and
Slc40a1C326S/C326S mice (Fig. S2A). A lack of oxidative stress in iron-
loaded AM may be explained by an adaptation to chronic iron accu-
mulation. By contrast, acute iron treatment of bone marrow derivedmacrophages (BMDM) triggers the formation of oxidative radicals
(Fig. S2A). Despite increased numbers of AM in Slc40a1C326S/C326S
mice (Fig. 3B), and consistent with a lack of oxidative stress in AM,
we failed to detect differences in mRNA and protein levels of inﬂam-
matory cytokines (IL1β, IL6 and TNFα) in total lung or in the BAL su-
pernatant, respectively (Fig. S2B, S2C). These observations indicate
that increased pulmonary iron levels did not cause pulmonary in-
ﬂammation in Slc40a1C326S/C326S mice.
3.4. Slc40a1C326S/C326S Mice Show Restrictive Lung Disease and Decreased
Blood Oxygen Saturation
Although no differences in lung structure were observed by his-
tological analysis (Fig. S3A-D), we next investigated whether
Slc40a1C326S/C326S mice show alterations in lung function. Func-
tional measurements in 36-week old Slc40a1C326S/C326S mice
revealed classical signs of restrictive lung disease, such as de-
creased total lung capacity and decreased lung compliance (Fig.
4A, B). Consistently, Slc40a1C326S/C326S mice show increased pul-
monary elastance, thus revealing elevated lung rigidity (Fig. 4C).
This observation was conﬁrmed by exposing the mice to ﬁxed air
pressures (Flexivent) as shown in the pressure-volume curve
(Fig. 4D). We excluded the possibility that the observed differences
between wild-type and Slc40a1C326S/C326S mice were due to differences
in body size. Despite the fact that aged Slc40a1C326S/C326S mice present
with lower body weight most likely due to exocrine pancreatic failure
(Altamura et al., 2014), the tibia length, a marker for body size, is com-
parable to age-matchedwild-typemice (Fig. S4A). Furthermore, we de-
tected a decrease in total lung capacity already in 26-week old
Slc40a1C326S/C326S mice, which at this age still don't show differences
in body weight as well as tibia length (Figs. S4, S5). Stereological analy-
sis of the lung shows that the volume of the lung parenchyma is reduced
in Slc40a1C326S/C326S mice, without alterations in the volume of the lung
non-parenchyma (Fig. 4E, F). These observations indicate that the de-
crease in total lung capacity of Slc40a1C326S/C326S mice results from a re-
duction in the volume of the lung parenchyma.
A major function of the lung is to provide optimal diffusion condi-
tions for efﬁcient oxygen exchange between the atmosphere and the
blood stream. Aged Slc40a1C326S/C326S mice show a marked reduction
in blood oxygen saturation when compared to wild-type mice (Fig.
4G). Systemic hypoxia is mainly sensed by the kidney which responds
by producing the erythroid growth factor, erythropoietin (Epo). Consis-
tent with decreased oxygen saturation, plasma Epo levels are increased
in Slc40a1C326S/C326S mice (Fig. 4 H). Increased levels of circulating Epo
stimulate erythropoiesis in the bone marrow to restore sufﬁcient oxy-
gen delivery to every cell in the organism. In line with these ﬁndings,
we observed higher levels of red blood cells, hemoglobin and hemato-
crit in Slc40a1C326S/C326S mice (Table S1) (Altamura et al., 2014).
4. Discussion
Respiratory diseases are frequently associated with alterations in
pulmonary iron homeostasis (Ghio, 2009). Patients with acute respira-
tory distress syndrome, pulmonary alveolar proteinosis, cystic ﬁbrosis
and COPD show higher levels of iron in the lung when compared to
healthy individuals (Ghio et al., 2003; Ghio et al., 2012; Ghio et al.,
2008; Philippot et al., 2014). So far, themechanism(s) leading to pulmo-
nary iron accumulation and the role of iron in the development of lung
diseases remain unexplored.
Here, we show that the genetic disruption of the regulatory system
maintaining systemic iron homeostasis causes age-dependent and ge-
notype-speciﬁc pulmonary iron accumulation, increased lipid peroxida-
tion, and gene responses consistent with pulmonary iron overload and
oxidative stress; TfR1 and DMT1-IRE expression is decreased and FtL
and FPN levels are increased. Elevated FPN protein levels likely result
from a combination of transcriptional responses, derepression of FPN
Fig. 3.Alveolarmacrophages in Slc40a1C326S/C326S mice show iron deposition. A)May-Grünwald-Giemsa of cytospin preparations of AMobtained from the BAL of male 26-week oldmice.
B) Total cell count and AMcell count of the BAL ﬂuid ofmale 26-week oldmice. C)Gating strategy used to identify the cells present in the BAL ﬂuid ofwild-type and Slc40a1C326S/C326Smice
by FACS analysis. D) Percentage of AM (CD11c+ SiglecF+) present in the leukocyte fraction (CD45.2+) in the BAL ﬂuid ofmale 24-week oldmice. E) Perls' stain of cytospin preparations of
cells isolated from the BAL ﬂuid of male 24-week oldmice. Arrow points to an iron spared AM. F) Immunocytochemistry for ferroportin in cytospin preparations of cells isolated from the
BAL ﬂuid of male 24-week old mice.
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that post-translationally stabilizes the FPN protein (Altamura et al.,
2014; Anderson et al., 2012).Our ﬁnding that increased systemic iron levels result in iron accu-
mulation in the lung is supported by a previous study inwhich intraper-
itoneal injection of iron-saccharate increased iron levels in the lung
Fig. 4. Impaired lung function and reduced blood oxygen saturation hallmark Slc40a1C326S/C326Smice. (A–D) Lung functionmeasurements performed in female 36-week oldmice. A) Total
Lung Capacity; B) Dynamic Compliance; C) Elastance; D) Pressure-Volume (PV) curve with controlled pressure applied. E) Volume of lung parenchymameasured in female 36-week old
mice. F) Volume of lung non-parenchymameasured in female 36-week oldmice. G) Blood oxygen saturationmeasured in female 36-week oldmice. H) Epo levelsmeasured in the plasma
of female 36-week old mice.
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nantly in AM, we demonstrate that in addition ciliated airway epi-
thelial cells, alveolar type II cells and vascular SMCs can load iron in
Slc40a1C326S/C326S mice. The differences observed in these two
mouse models of iron overload may be explained by an acute versus
chronic iron overload, by different iron sources or possible local con-
sequences of the disrupted FPN/hepcidin system.
We further show that iron accumulation in Slc40a1C326S/C326S mice
does not trigger pulmonary inﬂammation. However, the availability of
free iron in the lung may determine the outcome of pulmonary infec-
tions (Khiroya and Turner, 2015). For example, increased pulmonary
iron levels are related to the persistence of Pseudomonas aeruginosa in-
fection in cystic ﬁbrosis patients (Reid et al., 2007). Moreover, during
Pseudomonas aeruginosa infection, themurine host up-regulates the ex-
pression of proteins involved in iron-sequestration (Damron et al.,
2016), highlighting the known competition for iron between the hostand the pathogen. Since there is a general increase in pulmonary iron
levels in Slc40a1C326S/C326S mice, and in particular in extracellular iron
in the bronchoalveolar space, we hypothesize that Slc40a1C326S/C326S
mice may have an increased susceptibility to bacterial lung infections.
However, this concept needs to be tested experimentally in future
studies.
Slc40a1C326S/C326S mice present classical signs of restrictive lung dis-
ease, with a decrease in total lung capacity and compliance and an in-
crease in pulmonary elastance. A restrictive pattern is commonly
associated with pulmonary ﬁbrosis but collagen deposition in the lung
of Slc40a1C326S/C326S mice is not signiﬁcantly increased and therefore
cannot explain the strong phenotype. Rodriguez-Capote and colleagues
showed that the presence of ROS and the oxidation of surfactant phos-
pholipids and proteins can alter surfactant function (Rodriguez-Capote
et al., 2006). It is thus possible that the presence of extracellular iron
in the bronchoalveolar space of Slc40a1C326S/C326S mice may affect
238 J. Neves et al. / EBioMedicine 20 (2017) 230–239surfactant activity, surface tension and lung compliance. However, the
mechanism(s) causing the restrictive pattern in Slc40a1C326S/C326S
mice still remain to be elucidated.
It is of note that restrictive lung disease is the predominant pulmo-
nary dysfunction in patients with thalassemia major (Carnelli et al.,
2003; Guidotti et al., 2016; Kanj et al., 2000). Due to ineffective erythro-
poiesis and blood transfusion requirements, these patients present with
increased systemic iron levels and parenchymal iron overload. We
therefore speculate that the pulmonary restrictive pattern in thalasse-
mia major patients may be a consequence of increased systemic iron
levels and/or lung iron deposition (Carnelli et al., 2003; Kanj et al.,
2000; Parakh et al., 2007).
Slc40a1C326S/C326S mice show a strong decrease in blood oxygen sat-
uration, despite the absence of observable structural changes in the
lung. Thisﬁnding can be causedby 1) a substantial ventilation/perfusion
(V/Q) mismatch, 2) a shunt ﬂow of the blood in Slc40a1C326S/C326S mice
or 3) by a low cardiac output. With regard to the ﬁrst hypothesis, the
iron deposition observed in a subset of alveolar type II cells may lead
to regional impairment of surfactant production, which may in turn
cause a partial collapse of gas exchanging units resulting in ventila-
tion/perfusion mismatch and hypoxemia. Second, a shunting of unoxy-
genated blood across the heart or the lungs might be caused by
abnormal iron deposition in vascular smooth muscle cells leading to
the respective vascular dysfunction/abnormalities. Third, low cardiac
output could also contribute to such a phenotype by causing low venous
O2 andﬁnally low arterial O2 saturation. Future studieswill be necessary
to address these possibilities.
The decrease in blood oxygen saturation correlates with increased
plasma EPO levels in Slc40a1C326S/C326S mice. Hypoxia is the main
physiological inducer of EPO production in the kidney via the hypox-
ia inducible factor HIF2α/HIF1β heterodimer (Haase, 2010). In
Slc40a1C326S/C326S mice iron may also directly increase HIF-2α mRNA
translation by inhibiting the binding of IRPs to its 5′ UTR (Sanchez et
al., 2007). Increased plasma levels of EPO stimulate erythropoiesis in
the bone marrow. Consistently, we detected high levels of red blood
cells, hemoglobin and hematocrit in Slc40a1C326S/C326S mice.
We cannot exclude that pathophysiological consequences of iron
overload in Slc40a1C326S/C326S mice other than in the lung may con-
tribute to our observations. The restrictive pattern and decreased
blood oxygen saturation may be caused by a combination of high
iron levels in the lung as well as other impairments triggered by an
increase in systemic iron levels and organ iron deposition
(Altamura et al., 2014). To date, there is no evidence of lung pathol-
ogy in human patients with HH type 4. However, this may reﬂect
upon the fact that patients identiﬁed with the FPN C326S point mu-
tation were heterozygous (Sham et al., 2005) and clinical iron over-
load has been controlled by phlebotomy.
Taken together, our results show that a disruption in the hepcidin/
FPN regulatory system leads to an age-dependent pulmonary iron depo-
sition in speciﬁc lung cell types. Homozygous Slc40a1C326S/C326S mice
show restrictive lung disease and decreased blood oxygen saturation.
These observations implicate iron in lung pathology, which so far is
not considered a classical iron-related disorder. Moreover, we speculate
that an impaired lung function may contribute to the premature death
observed in Slc40a1C326S/C326S mice (Altamura et al., 2014).Funding Sources
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